<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Vaccines (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Vaccines (Basel)</journal-id><journal-id journal-id-type="pmc-domain-id">2764</journal-id><journal-id journal-id-type="pmc-domain">vaccines</journal-id><journal-id journal-id-type="publisher-id">vaccines</journal-id><journal-title-group><journal-title>Vaccines</journal-title></journal-title-group><issn pub-type="epub">2076-393X</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12474128</article-id><article-id pub-id-type="pmcid-ver">PMC12474128.1</article-id><article-id pub-id-type="pmcaid">12474128</article-id><article-id pub-id-type="pmcaiid">12474128</article-id><article-id pub-id-type="pmid">41012168</article-id><article-id pub-id-type="doi">10.3390/vaccines13090965</article-id><article-id pub-id-type="publisher-id">vaccines-13-00965</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Antibody Responses to SARS-CoV-2 and Common HCoVs in Hemodialysis Patients and Transplant Recipients: Data from the Dominican Republic</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-7339-1124</contrib-id><name name-style="western"><surname>Alcantara Sanchez</surname><given-names initials="L">Lisette</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><xref rid="af1-vaccines-13-00965" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-0120-588X</contrib-id><name name-style="western"><surname>Alvarez Guerra</surname><given-names initials="E">Eloy</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="af2-vaccines-13-00965" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9140-2483</contrib-id><name name-style="western"><surname>Li</surname><given-names initials="D">Dongmei</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><xref rid="af1-vaccines-13-00965" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3568-7597</contrib-id><name name-style="western"><surname>King</surname><given-names initials="SM">Samantha M.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="af3-vaccines-13-00965" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1950-7381</contrib-id><name name-style="western"><surname>Hilchey</surname><given-names initials="SP">Shannon P.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="af3-vaccines-13-00965" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0003-9215-8808</contrib-id><name name-style="western"><surname>Zhou</surname><given-names initials="Q">Qian</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="af3-vaccines-13-00965" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-7729-7920</contrib-id><name name-style="western"><surname>Dewhurst</surname><given-names initials="S">Stephen</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af4-vaccines-13-00965" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3613-8012</contrib-id><name name-style="western"><surname>Fiscella</surname><given-names initials="K">Kevin</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af5-vaccines-13-00965" ref-type="aff">5</xref><xref rid="fn1-vaccines-13-00965" ref-type="author-notes">&#8224;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-7095-8682</contrib-id><name name-style="western"><surname>Zand</surname><given-names initials="MS">Martin S.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af1-vaccines-13-00965" ref-type="aff">1</xref><xref rid="af3-vaccines-13-00965" ref-type="aff">3</xref><xref rid="af6-vaccines-13-00965" ref-type="aff">6</xref><xref rid="c1-vaccines-13-00965" ref-type="corresp">*</xref><xref rid="fn1-vaccines-13-00965" ref-type="author-notes">&#8224;</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Pincus</surname><given-names initials="S">Seth</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-vaccines-13-00965"><label>1</label>Clinical and Translational Science Institute, University of Rochester, Rochester, NY 14642, USA; <email>lisette_alcantara@urmc.rochester.edu</email> (L.A.S.); <email>dongmei_li@urmc.rochester.edu</email> (D.L.)</aff><aff id="af2-vaccines-13-00965"><label>2</label>Instituto Nacional de Coordinaci&#243;n de Trasplante, Santo Domingo 10103, Dominican Republic; <email>eloydaniel.ag@gmail.com</email></aff><aff id="af3-vaccines-13-00965"><label>3</label>Department of Medicine, Division of Nephrology, University of Rochester, Rochester, NY 14642, USA; <email>samantha_king@urmc.rochester.edu</email> (S.M.K.); <email>shannon_hilchey@urmc.rochester.edu</email> (S.P.H.); <email>qian_zhou@urmc.rochester.edu</email> (Q.Z.)</aff><aff id="af4-vaccines-13-00965"><label>4</label>Department Microbiology and Immunology, University of Rochester, Rochester, NY 14642, USA; <email>stephen_dewhurst@urmc.rochester.edu</email></aff><aff id="af5-vaccines-13-00965"><label>5</label>Department of Family Medicine, University of Rochester, Rochester, NY 14642, USA; <email>kevin_fiscella@urmc.rochester.edu</email></aff><aff id="af6-vaccines-13-00965"><label>6</label>Department of Public Health Sciences, University of Rochester, Rochester, NY 14642, USA</aff><author-notes><corresp id="c1-vaccines-13-00965"><label>*</label>Correspondence: <email>martin_zand@urmc.rochester.edu</email></corresp><fn id="fn1-vaccines-13-00965"><label>&#8224;</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="epub"><day>11</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>9</month><year>2025</year></pub-date><volume>13</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">497676</issue-id><elocation-id>965</elocation-id><history><date date-type="received"><day>15</day><month>7</month><year>2025</year></date><date date-type="rev-recd"><day>29</day><month>8</month><year>2025</year></date><date date-type="accepted"><day>10</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>11</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>28</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-28 18:25:14.327"><day>28</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="vaccines-13-00965.pdf"/><abstract><p><bold>Background:</bold> Vaccination against SARS-CoV-2 has been pivotal in controlling the COVID-19 pandemic. However, understanding vaccine-induced immunity in immunocompromised individuals remains critical, particularly how prior exposure to other coronaviruses modulates immune responses. The influence of previous infections with endemic human coronaviruses (HCoVs), such as OC43, on SARS-CoV-2 immunity is not fully understood. This study evaluates antibody responses to COVID-19 vaccination in hemodialysis patients (HD), transplant recipients (TR), and healthy controls (CO), accounting for prior SARS-CoV-2 infection and baseline human coronavirus (HCoV) reactivity. <bold>Methods:</bold> We obtained longitudinal antibody measurements from 70 subjects (CO: <italic toggle="yes">n</italic> = 33; HD: <italic toggle="yes">n</italic> = 13; TR: <italic toggle="yes">n</italic> = 24) and assessed antibody kinetics across multiple post-vaccination time points using multivariate linear mixed modeling (MLMM). <bold>Results:</bold> Limited but measurable cross-reactivity was observed between SARS-CoV-2 and endemic HCoVs, particularly the <inline-formula><mml:math id="mm1" overflow="scroll"><mml:mrow><mml:mi>&#946;</mml:mi></mml:mrow></mml:math></inline-formula>-coronavirus OC43. Pre-existing immunity in healthy individuals modestly enhanced vaccine-induced anti-spike (S) IgG responses, supported by post-vaccination increases in SARS-CoV-2 IgG. Prior SARS-CoV-2 infection significantly influenced anti-S and nucleocapsid (N) IgG responses but had limited impact on endemic HCoVs responses. Vaccine type and immune status significantly affected antibody kinetics. mRNA vaccination (BNT162b2) elicited stronger and more durable SARS-CoV-2 anti-S IgG responses than the inactivated CoronaVac vaccine, especially in immunocompetent individuals. Immunocompromised groups showed delayed or attenuated responses, with modest anti-S IgG cross-reactive boosting. Elevated anti-N IgG in CoronaVac recipients raised questions about its origin&#8212;infection or vaccine effects. MLMM identified key immunological and clinical predictors of antibody responses, emphasizing the critical role of host immune history. <bold>Conclusions:</bold> These findings highlight a constrained but meaningful role for HCoV cross-reactivity in SARS-CoV-2 immunity and vaccine responsiveness, underscore the need for infection markers unaffected by vaccination, and support development of broadly protective pan-coronavirus vaccines and tailored strategies for at-risk populations.</p></abstract><kwd-group><kwd>COVID-19</kwd><kwd>SARS-CoV-2 vaccine</kwd><kwd>transplant recipients</kwd><kwd>hemodialysis</kwd><kwd>immunocompromised</kwd><kwd>common human coronavirus</kwd><kwd>cross-reactivity</kwd><kwd>antibody response</kwd><kwd>anti-S</kwd><kwd>anti-N</kwd></kwd-group><funding-group><award-group><funding-source>the University of Rochester Clinical and Translational Science Awards</funding-source><award-id>UL1 TR002001</award-id><award-id>TL1 TR002000</award-id></award-group><funding-statement>This research was funded by the University of Rochester Clinical and Translational Science Awards (UL1 TR002001, TL1 TR002000) from the National Center for Advancing Translational Sciences of the National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-vaccines-13-00965"><title>1. Introduction</title><p>The emergence of SARS-CoV-2 has highlighted the importance of understanding immune cross-reactivity with human coronaviruses (HCoVs), as it may impact disease progression, vaccine efficacy, and diagnostic accuracy [<xref rid="B1-vaccines-13-00965" ref-type="bibr">1</xref>,<xref rid="B2-vaccines-13-00965" ref-type="bibr">2</xref>,<xref rid="B3-vaccines-13-00965" ref-type="bibr">3</xref>]. Cross-reactivity occurs when an immune response, such as antibody production, targets similar antigens from different HCoV strains due to shared epitopes on surface proteins, potentially leading to diagnostic challenges or unintended immune effects [<xref rid="B2-vaccines-13-00965" ref-type="bibr">2</xref>,<xref rid="B4-vaccines-13-00965" ref-type="bibr">4</xref>,<xref rid="B5-vaccines-13-00965" ref-type="bibr">5</xref>]. SARS-CoV-2, a <inline-formula><mml:math id="mm2" overflow="scroll"><mml:mrow><mml:mi>&#946;</mml:mi></mml:mrow></mml:math></inline-formula>-coronavirus, shares structural similarities with other HCoVs, particularly in its spike (S) and nucleocapsid (N) proteins, which can trigger cross-reactive immune responses [<xref rid="B2-vaccines-13-00965" ref-type="bibr">2</xref>,<xref rid="B3-vaccines-13-00965" ref-type="bibr">3</xref>,<xref rid="B5-vaccines-13-00965" ref-type="bibr">5</xref>,<xref rid="B6-vaccines-13-00965" ref-type="bibr">6</xref>]. Pre-existing immunity to seasonal <inline-formula><mml:math id="mm3" overflow="scroll"><mml:mrow><mml:mi>&#945;</mml:mi></mml:mrow></mml:math></inline-formula>-(229E, NL63) and <inline-formula><mml:math id="mm4" overflow="scroll"><mml:mrow><mml:mi>&#946;</mml:mi></mml:mrow></mml:math></inline-formula>-coronaviruses (OC43, HKU1) may alter immune responses to SARS-CoV-2 through antigenic cross-reactivity [<xref rid="B2-vaccines-13-00965" ref-type="bibr">2</xref>,<xref rid="B4-vaccines-13-00965" ref-type="bibr">4</xref>]. In immunocompromised individuals, such as hemodialysis patients (HD) and transplant recipients (TR), cross-reactivity may impair vaccine efficacy or viral clearance, increasing the risk of severe COVID-19 [<xref rid="B7-vaccines-13-00965" ref-type="bibr">7</xref>].</p><p>At the molecular level, SARS-CoV-2 and other HCoVs share key features, such as the receptor-binding domain (RBD) of the S1 subunit, which mediates viral entry via the angiotensin-converting enzyme 2 (ACE2) receptor, and serves as a primary vaccine target [<xref rid="B8-vaccines-13-00965" ref-type="bibr">8</xref>,<xref rid="B9-vaccines-13-00965" ref-type="bibr">9</xref>]. Cross-reactive antibodies from prior infections with endemic human coronaviruses (HCoVs) may provide partial immunity to SARS-CoV-2, potentially influencing disease severity, vaccine effectiveness, and immune responses [<xref rid="B1-vaccines-13-00965" ref-type="bibr">1</xref>,<xref rid="B5-vaccines-13-00965" ref-type="bibr">5</xref>,<xref rid="B8-vaccines-13-00965" ref-type="bibr">8</xref>,<xref rid="B10-vaccines-13-00965" ref-type="bibr">10</xref>,<xref rid="B11-vaccines-13-00965" ref-type="bibr">11</xref>]. However, the precise role of this cross-reactivity remains under investigation, including concerns regarding the theoretical risk of antibody-dependent enhancement (ADE) [<xref rid="B5-vaccines-13-00965" ref-type="bibr">5</xref>,<xref rid="B8-vaccines-13-00965" ref-type="bibr">8</xref>]. The widespread circulation of multiple HCoVs further complicates the assessment of past infections and the evaluation of vaccine-induced immunity, particularly in regions where these viruses co-exist [<xref rid="B1-vaccines-13-00965" ref-type="bibr">1</xref>,<xref rid="B10-vaccines-13-00965" ref-type="bibr">10</xref>,<xref rid="B11-vaccines-13-00965" ref-type="bibr">11</xref>]. Moreover, cross-reactivity poses significant challenges for serological diagnostics, as antibodies targeting shared epitopes may result in false-positive findings, thereby affecting clinical and epidemiological interpretations [<xref rid="B2-vaccines-13-00965" ref-type="bibr">2</xref>,<xref rid="B3-vaccines-13-00965" ref-type="bibr">3</xref>,<xref rid="B5-vaccines-13-00965" ref-type="bibr">5</xref>,<xref rid="B12-vaccines-13-00965" ref-type="bibr">12</xref>]. These challenges underscore the need for multiplex diagnostic assays and a clearer understanding of cross-reactive immunity to refine vaccination strategies and enhance public health interventions, especially for vulnerable populations [<xref rid="B13-vaccines-13-00965" ref-type="bibr">13</xref>,<xref rid="B14-vaccines-13-00965" ref-type="bibr">14</xref>,<xref rid="B15-vaccines-13-00965" ref-type="bibr">15</xref>]. Additionally, the impact of pre-existing immunity on disease severity appears to vary across populations, particularly among individuals with chronic kidney disease (CKD) and other comorbidities, thereby complicating clinical management [<xref rid="B14-vaccines-13-00965" ref-type="bibr">14</xref>,<xref rid="B16-vaccines-13-00965" ref-type="bibr">16</xref>].</p><p>Chronic kidney disease is a major health concern in the Dominican Republic, with 9358 active cases in 2023; among them, 5275 were on dialysis, including 4083 on hemodialysis [<xref rid="B17-vaccines-13-00965" ref-type="bibr">17</xref>]. Furthermore, approximately 500 individuals were on the kidney transplant waiting list, while 299 received a kidney transplant between 2019 and 2023 [<xref rid="B18-vaccines-13-00965" ref-type="bibr">18</xref>]. It is essential to gather data on the response to COVID-19 vaccines among individuals on hemodialysis (HD) and transplant recipients (TR) in the DR to better understand how factors such as demographics, environment, and prevalence of other common HCoV influence vaccine effectiveness, thereby improving healthcare outcomes locally and globally. The DR&#8217;s national vaccination campaign, launched in February 2021, prioritized high-risk groups, including those on HD and TR, due to their higher vulnerability to infection and severe outcomes [<xref rid="B19-vaccines-13-00965" ref-type="bibr">19</xref>]. Three vaccines were offered: BNT162b2 (Pfizer&#8211;BioNTech), AZD1222 (AstraZeneca&#8211;Oxford), and CoronaVac (Sinovac) [<xref rid="B20-vaccines-13-00965" ref-type="bibr">20</xref>]. By March 2024, 15 million doses had been administered to approximately 11 million individuals, with 68% having received at least one dose, and 56% fully vaccinated after two or more doses [<xref rid="B21-vaccines-13-00965" ref-type="bibr">21</xref>]. Despite this, there remains a lack of real-world or clinical trial data on vaccine responses in HD and TR patients in the DR. This is particularly important as local health and demographic factors, such as vaccine availability, access, and the ability to reach specific populations, can lead to significant variation in vaccine effectiveness.</p><p>Here, we report a secondary analysis of capillary blood samples that examines immune protection and cross-reactive immunity in high-risk populations by analyzing IgG responses to SARS-CoV-2 and four common circulating HCoVs (OC43, HKU1, 229E, NL63) in transplant recipients (TR) and hemodialysis patients (HD) in the Dominican Republic. As part of a study approved by Instituto Nacional de Coordinaci&#243;n de Trasplante (INCORT), we used a multiplex assay to simultaneously measure antibodies targeting the spike (S) and nucleocapsid (N) proteins of SARS-CoV-2 and the four common HCOV strains [<xref rid="B5-vaccines-13-00965" ref-type="bibr">5</xref>,<xref rid="B8-vaccines-13-00965" ref-type="bibr">8</xref>,<xref rid="B22-vaccines-13-00965" ref-type="bibr">22</xref>,<xref rid="B23-vaccines-13-00965" ref-type="bibr">23</xref>], while larger studies have examined antibody reactivity to SARS-CoV-2, no prior studies have looked at the correlation with antibodies directed against the common circulating coronaviruses in dialysis patients and renal transplant recipients, and none that we are aware of have comparison data for CoronaVac. This study also assessed potential cross-reactivity between SARS-CoV-2 and HCoVs, providing critical insights to refine diagnostic tools, inform vaccine strategies, and enhance clinical management of immunocompromised individuals.</p></sec><sec id="sec2-vaccines-13-00965"><title>2. Materials and Methods</title><sec id="sec2dot1-vaccines-13-00965"><title>2.1. Human Subjects Ethics Statement</title><p>This is the second report in a series of studies based on secondary analysis of capillary blood samples and de-identified data collected by INCORT in the Dominican Republic [<xref rid="B23-vaccines-13-00965" ref-type="bibr">23</xref>]. The original protocol was approved on 6 October 2020, by the National Health Bioethics Committee of the Dominican Republic (CONABIOS; INCORT.PI2020.004.01), with an amendment granting partial approval for our participation in 20 July 2021. The secondary analysis was subsequently approved in 12 January 2022 by the Institutional Review Board (IRB) at the University of Rochester Medical Center (IRB STUDY00006807). All research data were coded in accordance with the U.S. Department of Health and Human Services regulations for the protection of human subjects (45 CFR 46.101(b) (4)).</p></sec><sec id="sec2dot2-vaccines-13-00965"><title>2.2. Study Design and Sample Collection</title><p>The methodological framework of the INCORT parent study was detailed in a prior publication [<xref rid="B23-vaccines-13-00965" ref-type="bibr">23</xref>]. The study enrolled 70 subjects from four hospitals affiliated with the national transplant recipient registry, as well as from dialysis units at three major national referral centers in the Dominican Republic. A control group was recruited from three COVID-19 vaccination clinics located in Santo Domingo. Recruitment and data collection were facilitated by medical staff through telephone calls, in-person interactions during hemodialysis sessions, and follow-up visits with transplant recipients.</p><p>The study population included three cohorts: transplant recipients (TR, <italic toggle="yes">n</italic> = 24), hemodialysis patients (HD, <italic toggle="yes">n</italic> = 13), and healthy controls (CO, <italic toggle="yes">n</italic> = 33), each further stratified by SARS-CoV-2 infection history (<xref rid="vaccines-13-00965-f001" ref-type="fig">Figure 1</xref>). A total of 271 capillary blood samples were collected via volumetric absorptive micro-sampling (VAMS) prior to the administration of at least one dose of either the BNT162b2 (Pfizer-BioNTech) mRNA vaccine or the CoronaVac (Sinovac) inactivated SARS-CoV-2 vaccine. Sampling was conducted at five time points: baseline (Day 0, prior to the first vaccine dose), Day 21 or 28 (prior to the second dose, depending on the vaccine schedule), Day 42, and Day 70 (two and four weeks after the second dose), as well as prior to any booster dose, if administered, and six months after the final dose. The analysis included both homologous and heterologous booster regimens&#8212;homologous boosters involved the same vaccine as the primary series, while heterologous boosters used a different vaccine. For vaccine selection, subjects followed healthcare providers&#8217; recommendations based on the national COVID-19 vaccination guidelines of the Dominican Republic [<xref rid="B19-vaccines-13-00965" ref-type="bibr">19</xref>]. All samples, initially stored by INCORT, were sent to the University of Rochester Medical Center for analysis of SARS-CoV-2 IgG-mediated immunity using the mPlex assay [<xref rid="B5-vaccines-13-00965" ref-type="bibr">5</xref>,<xref rid="B8-vaccines-13-00965" ref-type="bibr">8</xref>,<xref rid="B22-vaccines-13-00965" ref-type="bibr">22</xref>,<xref rid="B23-vaccines-13-00965" ref-type="bibr">23</xref>].</p><p>The inclusion criteria of the parent study involved adults aged 18 or older who were either receiving hemodialysis or had undergone solid organ transplantation and were willing to receive a COVID-19 vaccine. To facilitate meaningful comparison with these immunocompromised cohorts, a control group was selected based on the absence of common medical conditions (i.e., hypertension, diabetes, cardiovascular disease, chronic respiratory conditions, immunodeficiency, and both degenerative and autoimmune diseases) that are known to elevate the risk of SARS-CoV-2 infection and severe outcomes [<xref rid="B24-vaccines-13-00965" ref-type="bibr">24</xref>]. Our sub-study excluded individuals who tested positive for COVID-19 via PCR at enrollment or had previously received any COVID-19 vaccine doses. Focusing on unvaccinated subjects enabled a longitudinal analysis of immune responses to subsequent COVID-19 vaccinations and infections from both SARS-CoV-2 and human coronaviruses (HCoVs), as well as key variables related to dialysis, organ transplantation, and COVID-19 vaccination status. As reported in the initial paper of this study series [<xref rid="B23-vaccines-13-00965" ref-type="bibr">23</xref>], the clinical variables are summarized in <xref rid="app1-vaccines-13-00965" ref-type="app">Supplementary Tables S1&#8722;S3</xref> (reproduced from that source).</p><p>Our analysis included data previously collected by INCORT through face-to-face interviews conducted by INCORT research personnel. These interviews included a self-reported questionnaire that gathered information on demographics, health status, and COVID-19 infection and vaccination history. Data compiled age, sex, race, ethnicity, highest level of education, and the number of vaccine doses received. This comprehensive set of variables was used in a Multivariate Linear Modeling to analyze the complex relationships between condition-specific factors, COVID-19 infection, vaccination status, and other health-related variables within the study population. Cohort demographics, COVID-19 infection, and vaccination status are summarized <xref rid="vaccines-13-00965-t001" ref-type="table">Table 1</xref>.</p></sec><sec id="sec2dot3-vaccines-13-00965"><title>2.3. mPlex-CoV Assay</title><p>All samples were collected as part of the parent study and processed in as described previously [<xref rid="B8-vaccines-13-00965" ref-type="bibr">8</xref>,<xref rid="B22-vaccines-13-00965" ref-type="bibr">22</xref>,<xref rid="B23-vaccines-13-00965" ref-type="bibr">23</xref>]. Antibodies were eluted from VAMS swabs by immersing them in 200 <inline-formula><mml:math id="mm5" overflow="scroll"><mml:mrow><mml:mi mathvariant="sans-serif">&#956;</mml:mi></mml:mrow></mml:math></inline-formula>L of extraction buffer (0.5% Tween 20, 1% BSA in PBS) at 4 &#176;C with gentle agitation overnight. The eluents were aliquoted into 100 <inline-formula><mml:math id="mm7" overflow="scroll"><mml:mrow><mml:mi mathvariant="sans-serif">&#956;</mml:mi></mml:mrow></mml:math></inline-formula>L tubes and stored at 4 &#176;C prior to multiplex assay analysis [<xref rid="B6-vaccines-13-00965" ref-type="bibr">6</xref>]. Quantified sample IgG concentrations targeting the SARS-CoV-2 spike (S) and nucleocapsid (N) protein antigens from various viral variants, including HCoVs (OC43, HKU1, 229E, NL63) as previously described [<xref rid="B5-vaccines-13-00965" ref-type="bibr">5</xref>,<xref rid="B8-vaccines-13-00965" ref-type="bibr">8</xref>,<xref rid="B22-vaccines-13-00965" ref-type="bibr">22</xref>]. Assay targets included recombinant, trimerized SARS-CoV-2 S- and N-proteins, as well as recombinant S1, S2, and RBD proteins (SinoBio, Beijing, China). Recombinant proteins were conjugated to magnetic microsphere beads (Luminex, Austin, TX, USA) at 40 pmole/106 beads as previously described. Eluent from VAMS devices (200 <inline-formula><mml:math id="mm9" overflow="scroll"><mml:mrow><mml:mi mathvariant="sans-serif">&#956;</mml:mi></mml:mrow></mml:math></inline-formula>L) for the IgG assay was diluted 1:1000. A total of 50 <inline-formula><mml:math id="mm10" overflow="scroll"><mml:mrow><mml:mi mathvariant="sans-serif">&#956;</mml:mi></mml:mrow></mml:math></inline-formula>L of the diluted sample was combined with 50 <inline-formula><mml:math id="mm11" overflow="scroll"><mml:mrow><mml:mi mathvariant="sans-serif">&#956;</mml:mi></mml:mrow></mml:math></inline-formula>L of the mPlex-CoV bead panel suspension and added to wells of 96-well plates in duplicate (Microplate, GBO, Kremsm&#252;nster, Austria). After washing, the bound IgG was detected with phycoerythrin-conjugated anti-human IgG (Southern Biotech, Birmingham, AL, USA, Cal No: 2040-09, 2050-09), and the median fluorescence intensity (MFI) was measured using a Luminex MagPix (R&amp;D Systems, Inc., Minneapolis, MN, USA) [<xref rid="B8-vaccines-13-00965" ref-type="bibr">8</xref>,<xref rid="B22-vaccines-13-00965" ref-type="bibr">22</xref>].</p></sec><sec id="sec2dot4-vaccines-13-00965"><title>2.4. Measurement of Hemoglobin (Hgb) and Adjustment of Antibody Concentration</title><p>We used hemoglobin (Hgb) values measured in the VAMS eluent to adjust capillary blood IgG concentrations for plasma volume, following published procedures [<xref rid="B6-vaccines-13-00965" ref-type="bibr">6</xref>,<xref rid="B23-vaccines-13-00965" ref-type="bibr">23</xref>]. From Hgb concentration, we calculated hematocrit and used it to refine IgG values, which allowed us to estimate serum IgG concentrations for SARS-CoV-2 and the seasonal coronaviruses OC43, HKU1, 229E, and NL63. To determine anti-S and anti-N IgG antibody concentrations, we applied standard curves generated from pooled positive sera controls, as described previously [<xref rid="B8-vaccines-13-00965" ref-type="bibr">8</xref>,<xref rid="B22-vaccines-13-00965" ref-type="bibr">22</xref>].</p></sec><sec id="sec2dot5-vaccines-13-00965"><title>2.5. Multidimensional Scaling (MDS) and Multivariate Linear Mixed Model (MLMM) Statistical Analysis</title><p>The demographics, subject characteristics, vaccination history details, and the status of the COVID-19 infection are summarized using frequency distributions and summary statistics. We evaluated the differences between study groups using chi-square or Fisher&#8217;s exact tests for categorical variables (<xref rid="vaccines-13-00965-t001" ref-type="table">Table 1</xref>).</p><p>Multidimensional Scaling (MDS) analysis of anti-S and anti-N IgG for common HCoVs&#8212;OC43, HKU1, 229E, NL63 was used to examine their association with anti-S and anti-N IgG SARS-CoV-2, identify groups, and reduce complexity. Using pairwise distances among HCoV-specific IgGs, MDS was applied to produce a set of dimensions that capture the main patterns in these variables. The first few MDS-derived dimensions, which accounted for the most variance, were selected as composite predictors and incorporated into the MLMM [<xref rid="B25-vaccines-13-00965" ref-type="bibr">25</xref>].</p><p>The MLMM was then fitted with these MDS-derived dimensions as predictors of the outcomes (anti-S and anti-N IgG SARS-CoV-2 IgG), effectively reducing multicollinearity and improving interpretability. The model was specified with appropriate fixed effects (e.g., the MDS dimensions) and random effects (e.g., grouping by cohort, prior COVID-19 infection, vaccine type), preserving the hierarchical structure of the data. The MLMM was then estimated with the coefficients for the MDS-derived predictors, assessing the relationships with SARS-CoV-2 anti-S IgG concentrations while accounting for random effects. MDS visualizations highlighted study groups and trends in anti-S IgG that aligned with the relationships captured by the MLMM coefficients. This combined approach facilitated dimensionality reduction, improved model stability, and clarified key patterns between SARS-CoV-2 anti-S IgG levels and anti-S IgG for common HCoVs. By leveraging both statistical inference (via MLMMs) and exploratory visualization (via MDS), we gained robust insights into our complex multivariate dataset.</p><p>Statistical analysis was performed using R version 3.5.1 (R Core Team, 2017). The significance level for all tests was set at <italic toggle="yes">p</italic> &lt; 0.05.</p></sec></sec><sec sec-type="results" id="sec3-vaccines-13-00965"><title>3. Results</title><sec id="sec3dot1-vaccines-13-00965"><title>3.1. Participant Characteristics, Vaccination Status, and COVID-19 History</title><p>As reported in the first paper of this series, the population included 70 subjects across three cohorts: Control (CO, <italic toggle="yes">n</italic> = 33), Hemodialysis (HD, <italic toggle="yes">n</italic> = 13), and Transplant Recipients (TR, <italic toggle="yes">n</italic> = 24) [<xref rid="B23-vaccines-13-00965" ref-type="bibr">23</xref>]. We found no statistically significant differences in age or gender among cohorts (<italic toggle="yes">p</italic> = 0.150), although males comprised a higher proportion of the HD and TR groups (57%) (<xref rid="vaccines-13-00965-t001" ref-type="table">Table 1</xref>). Most subjects self-identified as Black and Hispanic or Latino (<italic toggle="yes">p</italic> &lt; 0.001), reflecting Dominican Republic demographics, where 74% of the population self-identifies as mixed race [<xref rid="B26-vaccines-13-00965" ref-type="bibr">26</xref>,<xref rid="B27-vaccines-13-00965" ref-type="bibr">27</xref>]. We observed significantly higher educational attainment in the TR cohort (<italic toggle="yes">p</italic> &lt; 0.001). Overall, 44% of subjects reported prior COVID-19 infection or a positive test result before vaccination. Recruitment imbalances across cohorts were primarily driven by early vaccination campaigns that prioritized high-risk populations, such as individuals on dialysis or post-transplant [<xref rid="B19-vaccines-13-00965" ref-type="bibr">19</xref>]. As a result, INCORT reported that enrolling unvaccinated participants had become increasingly difficult by the time the study began.</p><p>There were significant differences in SARS-CoV-2 vaccination status across cohorts (<italic toggle="yes">p</italic> &lt; 0.001), with the TR group showing the highest rate of full vaccination with one booster dose (42%), while vaccine type and booster regimen distribution varied, these differences were not statistically significant (<italic toggle="yes">p</italic> = 0.066). Among subjects who received heterologous boosters, the most common sequence was an initial CoronaVac dose followed by a BNT162b2 booster. In contrast, homologous vaccination primarily involved two doses of BNT162b2 (87.5%), with only one participant receiving two doses of CoronaVac. Previous COVID-19 infection was reported more frequently in the TR group (63%) compared to the HD (46%) and CO (30%) groups, with these differences approaching statistical significance (<italic toggle="yes">p</italic> = 0.053). In contrast, there were no statistically significant differences in COVID-19 positivity during the study period, as only 21.43% of participants reported being aware of a positive test prior to enrollment.</p></sec><sec id="sec3dot2-vaccines-13-00965"><title>3.2. Co-Factor Analysis of Antibody Responses to SARS-CoV-2 and Common Human Coronaviruses (HCoVs)</title><p>We applied Multivariate Linear Modeling (MLMM) to examine the influence of multiple co-factors on IgG antibody responses to SARS-CoV-2 and common human coronaviruses (HCoVs), including OC43, HKU1, 229E, and NL63 (<xref rid="vaccines-13-00965-f002" ref-type="fig">Figure 2</xref>). This analysis enabled the evaluation of the relative contributions of variables, including COVID-19 vaccination history, prior SARS-CoV-2 infection, and immunocompromised status, to the development of antibody levels before and after vaccination. Among these factors, prior SARS-CoV-2 infection and vaccine type emerged as the strongest predictors of elevated anti-Spike IgG levels (left panel).</p><p>A history of self-reported COVID-19 positivity prior to vaccination was significantly associated with increased SARS-CoV-2 anti-S IgG responses (<italic toggle="yes">p</italic> = 0.001). Additionally, a highly significant interaction between cohort and prior SARS-CoV-2 infection (<italic toggle="yes">p</italic> &lt; 0.001) indicated that individuals with hybrid immunity, defined as natural infection followed by vaccination, had the highest antibody levels (<xref rid="vaccines-13-00965-f002" ref-type="fig">Figure 2</xref>, left panel). Vaccine type also influenced responses; CoronaVac priming was associated with a modest but significant increase in anti-S IgG levels (<italic toggle="yes">p</italic> = 0.021), though its effect on cross-reactive responses was limited. In relation to cross-reactivity with common circulating HCoVs, prior SARS-CoV-2 infection was associated with significantly higher anti-S IgG levels against OC43 (<italic toggle="yes">p</italic> = 0.004) and HKU1 (<italic toggle="yes">p</italic> = 0.012), also <inline-formula><mml:math id="mm12" overflow="scroll"><mml:mrow><mml:mi>&#946;</mml:mi></mml:mrow></mml:math></inline-formula>-corona virus strains, suggesting cross-reactive immune responses.</p><p>Findings supporting cross-reactive responses were further corroborated by correlation analyses (<xref rid="app1-vaccines-13-00965" ref-type="app">Supplementary Figure S1</xref>), which demonstrated significant positive associations between SARS-CoV-2 anti-S IgG antibodies and those targeting common HCoVs. Moderate correlations were observed between SARS-CoV-2 anti-S IgG and the <inline-formula><mml:math id="mm13" overflow="scroll"><mml:mrow><mml:mi>&#946;</mml:mi></mml:mrow></mml:math></inline-formula>-coronaviruses OC43 (<inline-formula><mml:math id="mm14" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mo>=</mml:mo><mml:mn>0.477</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula>) and HKU1 (<inline-formula><mml:math id="mm15" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mo>=</mml:mo><mml:mn>0.541</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula>), while weaker correlations were noted with the <inline-formula><mml:math id="mm16" overflow="scroll"><mml:mrow><mml:mi>&#945;</mml:mi></mml:mrow></mml:math></inline-formula>-coronaviruses 229E (<inline-formula><mml:math id="mm17" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mo>=</mml:mo><mml:mn>0.295</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula>) and NL63 (<inline-formula><mml:math id="mm18" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mo>=</mml:mo><mml:mn>0.353</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula>). The strongest correlation was detected between the <inline-formula><mml:math id="mm19" overflow="scroll"><mml:mrow><mml:mi>&#946;</mml:mi></mml:mrow></mml:math></inline-formula>-HCoVs OC43 and HKU1 (<inline-formula><mml:math id="mm20" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mo>=</mml:mo><mml:mn>0.877</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula>, <italic toggle="yes">p</italic> &lt; 0.001). Furthermore, stratification by cohort revealed stronger inter-virus correlations in the HD and TR groups compared to CO, particularly between SARS-CoV-2 and OC43 (HD: <inline-formula><mml:math id="mm21" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mo>=</mml:mo><mml:mn>0.665</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula>; TR: <inline-formula><mml:math id="mm22" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mo>=</mml:mo><mml:mn>0.596</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula>). These findings suggest that altered immune status may facilitate broader or more interconnected antibody responses, consistent with the enhanced cross-reactivity identified in the MLMM [<xref rid="B2-vaccines-13-00965" ref-type="bibr">2</xref>,<xref rid="B10-vaccines-13-00965" ref-type="bibr">10</xref>,<xref rid="B12-vaccines-13-00965" ref-type="bibr">12</xref>,<xref rid="B16-vaccines-13-00965" ref-type="bibr">16</xref>].</p><p>For anti-N IgG responses (<xref rid="vaccines-13-00965-f002" ref-type="fig">Figure 2</xref>, right panel), MLMM analysis identified prior SARS-CoV-2 infection as the primary factor associated with elevated antibody levels (<italic toggle="yes">p</italic> &lt; 0.001). As expected, individuals with reported prior SARS-CoV-2 infection exhibited markedly higher SARS-CoV-2 anti-N IgG responses, along with increased anti-N IgG against common HCoVs, particularly HKU1 (<italic toggle="yes">p</italic> = 0.012), OC43 (<italic toggle="yes">p</italic> = 0.004), and to a lesser extent 229E (<italic toggle="yes">p</italic> = 0.013), suggesting potential cross-reactivity. In contrast, those without prior SARS-CoV-2 infection showed minimal anti-N IgG reactivity against HCoVs, consistent with limited nucleocapsid exposure. Additionally, similar to anti-S responses, the TR group demonstrated significantly reduced HCoVs anti-N IgG levels, underscoring the suppressive impact of immunosuppression on humoral immunity targeting nucleocapsid proteins.</p><p>Correlation analyses also supported these observations (<xref rid="app1-vaccines-13-00965" ref-type="app">Supplementary Figure S2</xref>), revealing moderate positive corlletions between SARS-CoV-2 anti-N IgG and antibody levels against common HCoVs: HKU1 (<inline-formula><mml:math id="mm23" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mo>=</mml:mo><mml:mn>0.543</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula>), 229E (<inline-formula><mml:math id="mm24" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mo>=</mml:mo><mml:mn>0.589</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula>), and OC43 (<inline-formula><mml:math id="mm25" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mo>=</mml:mo><mml:mn>0.456</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula>). Strong correlations were most pronounced in the HD cohort, with values reaching <inline-formula><mml:math id="mm26" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mo>=</mml:mo><mml:mn>0.708</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula> for SARS-CoV-2 vs. HKU1 and <inline-formula><mml:math id="mm27" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mo>=</mml:mo><mml:mn>0.845</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula> for OC43 vs. HKU1, suggesting heightened immune stimulation or broader cross-reactivity in this group. The TR cohort displayed moderate correlations, whereas controls exhibited weaker associations and generally lower antibody levels. Strong correlations between OC43 and HKU1 across all cohorts likely reflect their genetic similarity.</p></sec><sec id="sec3dot3-vaccines-13-00965"><title>3.3. Antibody Responses to SARS-CoV-2 and Common Human Coronaviruses in Hemodialysis, Transplant, and Control Groups</title><p>To examine SARS-CoV-2 vaccine-induced immune responses, potential cross-reactive effects with common human coronaviruses (HCoVs), and differences across three cohorts, we conducted longitudinal measurements of IgG concentrations targeting HCoV spike and nucleocapsid proteins in HD, TR, and CO (<xref rid="vaccines-13-00965-f003" ref-type="fig">Figure 3</xref>). We assessed changes in anti-S and anti-N IgG levels in relation to both SARS-CoV-2 and HCoVs responses. Virus-specific IgG profiles are presented in (<xref rid="app1-vaccines-13-00965" ref-type="app">Supplementary Figure S3</xref>). We hypothesized that higher HCoVs IgG levels correlate with stronger SARS-CoV-2 anti-S IgG responses post-vaccination and booster across all groups, with differences between HD, TR, and controls reflecting the extent and nature of immunocompromise, potentially affecting cross-reactivity. This analysis allowed us to evaluate how pre-existing B cell immunity to HCoVs may modulate humoral responses to COVID-19 vaccination and boosting.</p><p>At baseline, CO showed the highest anti-S IgG concentrations, particularly for SARS-CoV-2 (<italic toggle="yes">p</italic> &lt; 0.001), followed by OC43 (<italic toggle="yes">p</italic> = 0.022) and HKU1 (<italic toggle="yes">p</italic> &lt; 0.001), reflecting likely prior exposure (<xref rid="vaccines-13-00965-f003" ref-type="fig">Figure 3</xref>A). Following vaccination, SARS-CoV-2 anti-S IgG levels rose significantly over time across all three cohorts (<italic toggle="yes">p</italic> &lt; 0.001), with a markedly greater increase in individuals with prior SARS-CoV-2 infection (<italic toggle="yes">p</italic> &lt; 0.001), consistent with a strong secondary immune response, as detailed in <xref rid="vaccines-13-00965-f004" ref-type="fig">Figure 4</xref>. A significant interaction between COVID-19 infection history and vaccine type (<italic toggle="yes">p</italic> = 0.030) indicates that prior exposure modulates vaccine-induced immunity in a platform-dependent manner. These effects were more pronounced and sustained in recipients of BNT162b2 compared to CoronaVac, particularly within the CO and HD groups, as detailed in Figure 6. Among cohorts, the CO group exhibited a modest but consistent increase in SARS-CoV-2 anti-S IgG over time (<italic toggle="yes">p</italic> = 0.012), with levels remaining significantly higher than those targeting HCoVs anti-S (<italic toggle="yes">p</italic> &lt; 0.001). In the HD group, we observed a delayed and significant increase in anti-S IgG (<italic toggle="yes">p</italic> = 0.028). In contrast, the TR group showed modest and statistically significant responses across all time points (<italic toggle="yes">p</italic> &lt; 0.001), consistent with immunosuppression and B cell dysfunction.</p><p>SARS-CoV-2 anti-N IgG levels increased progressively after the second vaccine dose and booster&#8212;particularly, in the HD cohort (<italic toggle="yes">p</italic> = 0.016). In contrast, baseline anti-N IgG levels for OC43 (<italic toggle="yes">p</italic> &lt; 0.001) and NL63 (<italic toggle="yes">p</italic> &lt; 0.001) were significantly higher in the CO and TR cohorts compared to HD, indicating pre-existing immunity. However, no significant changes anti-N IgG levels were observed over time across cohorts (<italic toggle="yes">p</italic> = 0.110), suggesting potential differences in prior HCoV exposure among the groups.</p></sec><sec id="sec3dot4-vaccines-13-00965"><title>3.4. Anti-Spike and Anti-Nucleocapsid IgG Antibody Responses to SARS-CoV-2 and Common Human Coronaviruses in Previously Infected and Non-Infected Subjects</title><p>We evaluated the impact of prior SARS-CoV-2 infection and pre-existing immunity to HCoVs on vaccine-induced immune responses (<xref rid="vaccines-13-00965-f004" ref-type="fig">Figure 4</xref>). Anti-S IgG antibodies were measured at multiple time points and stratified by COVID-19 history and cohort. As hypothesized, prior SARS-CoV-2 infection was significantly associated with higher overall anti-S IgG levels following vaccination (<italic toggle="yes">p</italic> &lt; 0.001) (<xref rid="vaccines-13-00965-f004" ref-type="fig">Figure 4</xref>B). At the baseline (day 0), individuals with a history of SARS-CoV-2 infection exhibited significantly elevated responses to both SARS-CoV-2 anti-S and anti-N IgG compared to infection-naive subjects (anti-S: <italic toggle="yes">p</italic> &lt; 0.001; anti-N: <italic toggle="yes">p</italic> = 0.003), consistent with residual immunity from natural infection.</p><p>Following vaccination, a modest but statistically significant increase in OC43 anti-S IgG levels was observed over time (<italic toggle="yes">p</italic> = 0.025), particularly among individuals who received two or more vaccine doses (<italic toggle="yes">p</italic> = 0.017), suggesting potential cross-reactive boosting of anti-S IgG. Similarly, prior SARS-CoV-2 infection was associated with small but statistically significant increase antibody levels for 229E (<italic toggle="yes">p</italic> = 0.026), but not HKU1 (<italic toggle="yes">p</italic> = 0.230). For NL63, no significant differences were observed between individuals with and without prior infection, as responses remained low and stable across all three groups and timepoints in both cases. The CO group (<italic toggle="yes">p</italic> = 0.095), HD group (<italic toggle="yes">p</italic> = 0.026), and TR group (<italic toggle="yes">p</italic> = 0.011) exhibited similar overall trends.</p><p>For anti-N IgG responses, as anticipated, prior SARS-CoV-2 infection was the dominant predictor of elevated antibody levels at baseline (<xref rid="vaccines-13-00965-f005" ref-type="fig">Figure 5</xref>B). Individuals with prior infection exhibited markedly higher anti-N IgG levels against SARS-CoV-2 (<italic toggle="yes">p</italic> &lt; 0.001), along with evidence of cross-reactivity to OC43 (<italic toggle="yes">p</italic> = 0.004), NL63 (<italic toggle="yes">p</italic> &lt; 0.001), and 229E (<italic toggle="yes">p</italic> = 0.048). This pattern was not observed for HKU1 (<italic toggle="yes">p</italic> = 0.012), which consistently exhibited low levels over time. Conversely, individuals without prior infection showed minimal anti-N IgG reactivity, consistent with the absence of nucleocapsid antigen exposure through vaccination alone.</p><p>To assess the durability of the anti-N IgG response, we evaluated the interaction between time and prior infection status. The interaction term was negative and statistically significant for SARS-CoV-2 anti-N IgG antibodies (<italic toggle="yes">p</italic>) = 0.001), indicating a modest but significant decline in antibody levels over time among individuals with prior infection. Similarly, effect estimates over time for OC43 and NL43 (<italic toggle="yes">p</italic> = 0.510; <italic toggle="yes">p</italic> = 0.720, respectively) indicate these initially increased levels were not consistent across all time points, suggesting that COVID-19 infection does not broadly induce cross-reactive boosting of anti-N IgG responses.</p><p>Collectively, these findings show that prior SARS-CoV-2 infection strongly influences initial anti-N IgG responses to SARS-CoV-2 and HCoVs post-vaccination, but has limited impact on their persistence over time.</p></sec><sec id="sec3dot5-vaccines-13-00965"><title>3.5. Anti-Spike and Anti-Nucleocapsid IgG Antibody Responses to SARS-CoV-2 and Common Human Coronaviruses and Vaccine Type</title><p>We examined the influence of vaccine type on antibody responses among different patient cohorts, specifically comparing CoronaVac (inactivated virus vaccine) to BNT162b2 (mRNA vaccine) recipients across HD, TR, and CO. Our MLMM analysis revealed that vaccine type was significantly associated with antibody responses to several viral antigens (<xref rid="vaccines-13-00965-f002" ref-type="fig">Figure 2</xref>). Significant effects were observed for anti-S IgG responses to SARS-CoV-2 (<italic toggle="yes">p</italic> = 0.021), although the interaction between cohort and vaccine type did not achieve significance (<italic toggle="yes">p</italic> = 0.083) (<xref rid="vaccines-13-00965-f006" ref-type="fig">Figure 6</xref>). Similarly, days after the first dose and prior SARS-CoV-2 infection significantly influenced anti-S IgG response (<italic toggle="yes">p</italic> &lt; 0.001). Vaccine dose number was not a significant independent predictor in the adjusted models (<italic toggle="yes">p</italic> = 0.245).</p><p>Vaccine type-specific effects were particularly evident in individuals primed with BNT162b2 vaccine, who exhibited significantly higher SARS-CoV-2 anti-S IgG levels compared to those who received CoronaVac, especially within the CO group (estimate = &#8722;0.294, <italic toggle="yes">p</italic> = 0.003). Among HD, CoronaVac priming was associated with both lower peak antibody levels and a steeper decline over time (estimate = &#8722;0.122, <italic toggle="yes">p</italic> = 0.041). The most impaired response was observed in the TR group, where CoronaVac-primed individuals showed markedly reduced anti-S IgG levels (estimate = &#8722;0.629, <italic toggle="yes">p</italic> = 0.026), consistent with the effects of chronic immunosuppression.</p><p>Regarding cross-reactivity with HCoVs anti-S IgG responses, CoronaVac was associated with a significant increase in OC43 anti-S IgG levels (<italic toggle="yes">p</italic> = 0.079) and HKU1 anti-S IgG levels (<italic toggle="yes">p</italic> = 0.011). Cohort and vaccine type-interactions were also observed for OC43 (<italic toggle="yes">p</italic> = 0.048), with higher antibody responses in HD individuals vaccinated with CoronaVac. Additionally, for 229E anti-S IgG, vaccine type had a significant effect (<italic toggle="yes">p</italic> = 0.045) and a strong cohort by vaccine-type interaction (<italic toggle="yes">p</italic> &lt; 0.001), with CoronaVac vaccination showing reduced responses in TR (estimate = &#8722;0.452, <italic toggle="yes">p</italic> = 0.016). For anti-S IgG NL63, vaccine type was significant (<italic toggle="yes">p</italic> = 0.037); however, no notable interaction effects were detected, and antibody levels remained consistently low over time. Moreover, prior SARS-CoV-2 infection was linked with higher IgG responses to OC43 (<italic toggle="yes">p</italic> = 0.004) and HKU1 (<italic toggle="yes">p</italic> = 0.012), particularly in BNT162b2-vaccinated HD. CoronaVac-primed TR showed significantly diminished responses to HKU1 (<italic toggle="yes">p</italic> = 0.014) and 229E (<italic toggle="yes">p</italic> = 0.048), highlighting compromised breadth under immunosuppression.</p><p>These findings were reinforced by correlation analysis (<xref rid="app1-vaccines-13-00965" ref-type="app">Supplementary Figure S1</xref>). The strongest inter-virus IgG correlations were observed between OC43 and HKU1 (<inline-formula><mml:math id="mm28" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mo>=</mml:mo><mml:mn>0.877</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula>, (<italic toggle="yes">p</italic> &lt; 0.001). Anti-S IgG responses to SARS-CoV-2 were also positively correlated with OC43 in HD (<inline-formula><mml:math id="mm29" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mo>=</mml:mo><mml:mn>0.665</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula>) and TR (<inline-formula><mml:math id="mm30" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mo>=</mml:mo><mml:mn>0.596</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula>), while CO showed much weaker associations with 229E (<inline-formula><mml:math id="mm31" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mo>=</mml:mo><mml:mn>0.295</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula>). These patterns suggest that altered immune status in HD and TR cohorts leads to more interconnected or broadly reactive humoral responses.</p><p>Our analysis of anti-N IgG responses revealed that vaccine type significantly modulates the magnitude and kinetics of antibody production, with notable differences between CoronaVac and BNT162b2 recipients across cohorts (<xref rid="vaccines-13-00965-f007" ref-type="fig">Figure 7</xref>). A highly significant interaction between cohort and vaccine type (<italic toggle="yes">p</italic> &lt; 0.001) suggests that the influence of vaccine type on SARS-CoV-2 anti-N IgG responses varies substantially between groups.</p><p>CoronaVac recipients in the CO group showed elevated anti-N IgG to HKU1 (estimate = 0.162, <italic toggle="yes">p</italic> = 0.021), that suggests cross-reactive responses, likely due to the whole-virus nature of the vaccine. Similarly, in HD with hybrid immunity due to prior SARS-CoV-2 infection, CoronaVac further amplified anti-N IgG responses OC43 (<italic toggle="yes">p</italic> = 0.067) and HKU1 (<italic toggle="yes">p</italic> = 0.015), also suggesting cross-reactive response, while BNT162b2 vaccine, which lack N antigen, induced limited cross-reactivity. TR again showed reduced anti-N IgG responses overall, particularly to SARS-CoV-2 and HKU1 (estimate =&#8722;0.237, <italic toggle="yes">p</italic> = 0.014).</p><p>Correlation analysis (<xref rid="app1-vaccines-13-00965" ref-type="app">Supplementary Figure S2</xref>) revealed moderate interrelatedness among anti-N IgG responses. SARS-CoV-2 anti-N IgG correlated positively with HKU1 (<inline-formula><mml:math id="mm32" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mo>=</mml:mo><mml:mn>0.543</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula>), 229E (<inline-formula><mml:math id="mm33" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mo>=</mml:mo><mml:mn>0.589</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula>), and OC43 (<inline-formula><mml:math id="mm34" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mo>=</mml:mo><mml:mn>0.456</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula>). These associations were most pronounced in the HD cohort, where correlations peaked at <inline-formula><mml:math id="mm35" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mo>=</mml:mo><mml:mn>0.708</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula> (SARS-CoV-2 vs. HKU1) and <inline-formula><mml:math id="mm36" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mo>=</mml:mo><mml:mn>0.845</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula> (OC43 vs. HKU1), suggesting broader immune activation. TR displayed moderate correlations, while controls exhibited weaker associations.</p><p>Collectively, these findings indicate that vaccine type, prior exposure, and cohort immune competence influence not only the magnitude of anti-N IgG at baseline and post-vaccination but also the extent of cross-reactive responses, particularly among individuals with altered immune status. The data highlight the importance of cumulative nucleopcasid antigen exposure in shaping the humoral landscape.</p></sec></sec><sec sec-type="discussion" id="sec4-vaccines-13-00965"><title>4. Discussion</title><p>Clinical and immunological factors influence both the magnitude and cross-reactivity of IgG antibody responses to SARS-CoV-2 and related common human coronaviruses (HCoVs) [<xref rid="B15-vaccines-13-00965" ref-type="bibr">15</xref>,<xref rid="B28-vaccines-13-00965" ref-type="bibr">28</xref>,<xref rid="B29-vaccines-13-00965" ref-type="bibr">29</xref>,<xref rid="B30-vaccines-13-00965" ref-type="bibr">30</xref>,<xref rid="B31-vaccines-13-00965" ref-type="bibr">31</xref>], particularly in immunocompromised populations such as hemodialysis (HD) patients and transplant recipients (TR) [<xref rid="B32-vaccines-13-00965" ref-type="bibr">32</xref>,<xref rid="B33-vaccines-13-00965" ref-type="bibr">33</xref>]. Using multivariate linear modeling (MLMM), we systematically evaluated how pre-existing immunity to SARS-CoV-2 and HCoVs, vaccination status, and immune competence shape humoral responses to COVID-19 vaccination and boosting (<xref rid="vaccines-13-00965-f002" ref-type="fig">Figure 2</xref>). By examining antibody responses against spike and nucleocapsid proteins across multiple coronaviruses, we identified prior SARS-CoV-2 infection and vaccine type as the strongest predictors of broadly reactive IgG responses, while also revealing a complex interplay with cohort-specific factors in shaping spike-specific immunity. emphasizing the role of hybrid immunity in enhancing responses to both SARS-CoV-2 and endemic HCoVs, aligning with previous reports [<xref rid="B12-vaccines-13-00965" ref-type="bibr">12</xref>,<xref rid="B34-vaccines-13-00965" ref-type="bibr">34</xref>].</p><p>Hybrid immunity and repeated vaccination seems to enhanced IgG responses to SARS-CoV-2 and endemic HCoVs, though dose number was not an independent predictor after adjustment. Common HCoVs triggered some cross-reactive anti-N IgG, with modest gains in low responders using less immunogenic platforms. Prior exposure to <inline-formula><mml:math id="mm37" overflow="scroll"><mml:mrow><mml:mi>&#946;</mml:mi></mml:mrow></mml:math></inline-formula>-coronaviruses (e.g., OC43) boosted anti-S IgG post-vaccination&#8212;likely via memory B cells targeting conserved spike epitopes&#8212;especially in healthy individuals [<xref rid="B10-vaccines-13-00965" ref-type="bibr">10</xref>,<xref rid="B16-vaccines-13-00965" ref-type="bibr">16</xref>,<xref rid="B35-vaccines-13-00965" ref-type="bibr">35</xref>,<xref rid="B36-vaccines-13-00965" ref-type="bibr">36</xref>]. This effect was weaker in immunocompromised groups (HD, TR), and in some cases, absence of prior HCoVs immunity appeared to enhance de novo SARS-CoV-2 responses, reflecting complex immune imprinting dynamics [<xref rid="B30-vaccines-13-00965" ref-type="bibr">30</xref>,<xref rid="B37-vaccines-13-00965" ref-type="bibr">37</xref>].</p><p>Post-vaccination, anti-SARS-CoV-2 IgG increased in all groups&#8212;strongest in healthy individuals, delayed in HD, and reduced in TR&#8212;reflecting effects of uremia, inflammation, and immunosuppression [<xref rid="B1-vaccines-13-00965" ref-type="bibr">1</xref>,<xref rid="B33-vaccines-13-00965" ref-type="bibr">33</xref>,<xref rid="B38-vaccines-13-00965" ref-type="bibr">38</xref>,<xref rid="B39-vaccines-13-00965" ref-type="bibr">39</xref>,<xref rid="B40-vaccines-13-00965" ref-type="bibr">40</xref>]. Cross-reactive anti-S IgG to HCoVs remained mostly stable, with slight increases in HD and minimal change in TR (<xref rid="vaccines-13-00965-f003" ref-type="fig">Figure 3</xref>A). A significant OC43 anti-S IgG rise in healthy individuals likely stemmed from conserved S2-domain epitopes [<xref rid="B16-vaccines-13-00965" ref-type="bibr">16</xref>,<xref rid="B35-vaccines-13-00965" ref-type="bibr">35</xref>,<xref rid="B41-vaccines-13-00965" ref-type="bibr">41</xref>], with little nucleocapsid cross-reactivity, while cross-reactivity may aid protection or response speed [<xref rid="B30-vaccines-13-00965" ref-type="bibr">30</xref>], it could also misdirect immunity toward non-neutralizing targets, consistent with original antigenic sin [<xref rid="B35-vaccines-13-00965" ref-type="bibr">35</xref>,<xref rid="B37-vaccines-13-00965" ref-type="bibr">37</xref>].</p><p>Immunosuppressive therapies, including mTOR inhibitors, calcineurin inhibitors, and corticosteroids, markedly impair humoral responses to SARS-CoV-2 infection and vaccination [<xref rid="B39-vaccines-13-00965" ref-type="bibr">39</xref>,<xref rid="B42-vaccines-13-00965" ref-type="bibr">42</xref>,<xref rid="B43-vaccines-13-00965" ref-type="bibr">43</xref>,<xref rid="B44-vaccines-13-00965" ref-type="bibr">44</xref>]. In the TR group, most subjects were more than 25 months post-transplant (66.7%) and maintained on potent immunosuppressants, including Everolimus (70.8%) and Cyclosporine (79.2%) (<xref rid="app1-vaccines-13-00965" ref-type="app">Supplementary Table S3</xref>). Despite these therapies, longer transplant-to-vaccination intervals were associated with delayed but detectable antibody responses, suggesting partial immune recovery over time [<xref rid="B43-vaccines-13-00965" ref-type="bibr">43</xref>,<xref rid="B44-vaccines-13-00965" ref-type="bibr">44</xref>]. Nevertheless, antibody titers and neutralizing capacity remained substantially lower than in immunocompetent individuals [<xref rid="B43-vaccines-13-00965" ref-type="bibr">43</xref>,<xref rid="B44-vaccines-13-00965" ref-type="bibr">44</xref>].</p><p>In HD patients given BNT162b2, prior SARS-CoV-2 infection boosted anti-S IgG to OC43 and HKU1, aligning with past studies [<xref rid="B34-vaccines-13-00965" ref-type="bibr">34</xref>,<xref rid="B35-vaccines-13-00965" ref-type="bibr">35</xref>]. TR vaccinated with CoronaVac showed weaker responses to 229E and HKU1, suggesting vaccine type and immunosuppression limit cross-reactivity [<xref rid="B45-vaccines-13-00965" ref-type="bibr">45</xref>]. Correlations between OC43 and HKU1 IgG in HD and TR may reflect altered immunity or repeated exposures [<xref rid="B41-vaccines-13-00965" ref-type="bibr">41</xref>,<xref rid="B46-vaccines-13-00965" ref-type="bibr">46</xref>]. BNT162b2 consistently elicited higher and durable responses across groups (<xref rid="vaccines-13-00965-f006" ref-type="fig">Figure 6</xref>), confirming the stronger immunogenicity of mRNA vaccines compared to CoronaVac [<xref rid="B9-vaccines-13-00965" ref-type="bibr">9</xref>,<xref rid="B29-vaccines-13-00965" ref-type="bibr">29</xref>,<xref rid="B42-vaccines-13-00965" ref-type="bibr">42</xref>,<xref rid="B47-vaccines-13-00965" ref-type="bibr">47</xref>,<xref rid="B48-vaccines-13-00965" ref-type="bibr">48</xref>]. Although dose number was not an independent predictor, extra doses may benefit low responders using weaker platforms [<xref rid="B49-vaccines-13-00965" ref-type="bibr">49</xref>]. These findings support tailored strategies for immunocompromised patients, including personalized dosing and more immunogenic or adjuvanted vaccines [<xref rid="B40-vaccines-13-00965" ref-type="bibr">40</xref>,<xref rid="B42-vaccines-13-00965" ref-type="bibr">42</xref>,<xref rid="B49-vaccines-13-00965" ref-type="bibr">49</xref>,<xref rid="B50-vaccines-13-00965" ref-type="bibr">50</xref>,<xref rid="B51-vaccines-13-00965" ref-type="bibr">51</xref>].</p><p>Anti-N IgG responses were influenced by vaccine platform, infection history, and immune status (<xref rid="vaccines-13-00965-f002" ref-type="fig">Figure 2</xref>). CoronaVac recipients, particularly those previously infected, displayed elevated anti-N IgG against HCoVs like HKU1 and OC43, consistent with the broader antigenic profile of whole-virus vaccines [<xref rid="B48-vaccines-13-00965" ref-type="bibr">48</xref>,<xref rid="B52-vaccines-13-00965" ref-type="bibr">52</xref>] (<xref rid="vaccines-13-00965-f007" ref-type="fig">Figure 7</xref>). In contrast, BNT162b2, which lacks the nucleocapsid antigen, elicited minimal anti-N IgG responses [<xref rid="B29-vaccines-13-00965" ref-type="bibr">29</xref>,<xref rid="B52-vaccines-13-00965" ref-type="bibr">52</xref>]. Prior infection was the most significant driver of elevated anti-N IgG and cross-reactivity, reinforcing the importance of natural infection in broadening humoral responses [<xref rid="B16-vaccines-13-00965" ref-type="bibr">16</xref>,<xref rid="B35-vaccines-13-00965" ref-type="bibr">35</xref>,<xref rid="B52-vaccines-13-00965" ref-type="bibr">52</xref>]. Interestingly, TR subjects did not show markedly reduced anti-N IgG, while HD individuals with hybrid immunity demonstrated robust cross-reactivity, suggesting some compensatory mechanisms despite immune dysfunction [<xref rid="B47-vaccines-13-00965" ref-type="bibr">47</xref>]. Correlations between SARS-CoV-2 and HCoVs anti-N IgG responses, especially in HD, suggest cross-recognition of conserved epitopes [<xref rid="B41-vaccines-13-00965" ref-type="bibr">41</xref>,<xref rid="B46-vaccines-13-00965" ref-type="bibr">46</xref>].</p><p>Fluctuations in anti-N IgG levels may reflect reinfection or &#8220;back-boosting,&#8221; whereby prior exposure enhances existing immunity (<xref rid="vaccines-13-00965-f005" ref-type="fig">Figure 5</xref>B). These changes, observed alongside variations in anti-S IgG, likely reflect vaccine-induced immune recall rather than new infections [<xref rid="B30-vaccines-13-00965" ref-type="bibr">30</xref>,<xref rid="B31-vaccines-13-00965" ref-type="bibr">31</xref>,<xref rid="B53-vaccines-13-00965" ref-type="bibr">53</xref>]. This phenomenon was particularly notable among recipients of CoronaVac, a whole-virus vaccine that induces both anti-S and anti-N responses [<xref rid="B9-vaccines-13-00965" ref-type="bibr">9</xref>,<xref rid="B54-vaccines-13-00965" ref-type="bibr">54</xref>,<xref rid="B55-vaccines-13-00965" ref-type="bibr">55</xref>,<xref rid="B56-vaccines-13-00965" ref-type="bibr">56</xref>]. These findings are consistent with reports of back-boosting following vaccination or heterologous exposure [<xref rid="B29-vaccines-13-00965" ref-type="bibr">29</xref>,<xref rid="B30-vaccines-13-00965" ref-type="bibr">30</xref>]. However, the rapid decline in anti-N IgG levels among previously infected individuals, especially in TR, limits its utility as a reliable marker of prior infection in immunosuppressed patients, and the presence of N-protein in the CornaVac whole virus vaccine limits the utility of anti-N IgG in identifying infection up to 4&#8211;6 weeks post-vaccination [<xref rid="B30-vaccines-13-00965" ref-type="bibr">30</xref>].</p><p>The study population showed no significant differences in age or gender across cohorts, although a higher proportion of males was observed in the HD and TR groups (<xref rid="vaccines-13-00965-t001" ref-type="table">Table 1</xref>). The predominance of Black and Hispanic or Latino subjects is consistent with the demographic trends in the Dominican Republic, where race and ethnicity are categorized distinctly. The TR cohort demonstrated higher levels of educational attainment and vaccination coverage, reflecting the success of targeted public health interventions, while variations in prior SARS-CoV-2 infection rates and vaccine regimens were noted, these differences did not reach statistical significance, suggesting overall consistency in exposure and immunization practices across the cohorts.</p><p>Our study has several limitations, most notably the small sample sizes. The rapid vaccine rollout in the Dominican Republic presented challenges for INCORT in recruiting unvaccinated individuals, particularly among immunocompromised groups. Vaccine hesitancy among hemodialysis patients&#8212;possibly related to poor health&#8212;further reduced participation. In the CO group, lower vaccination rates likely reflect hesitancy among younger, healthier individuals and fewer interactions with healthcare services [<xref rid="B57-vaccines-13-00965" ref-type="bibr">57</xref>]. In contrast, delays in the HD group may be attributed to misinformation or inadequate provider-patient communication [<xref rid="B58-vaccines-13-00965" ref-type="bibr">58</xref>]. Nonetheless, recommendations from nephrologists have been shown to improve vaccine uptake [<xref rid="B58-vaccines-13-00965" ref-type="bibr">58</xref>]. In contrast, 92% of TR received two or more doses, likely due to higher education levels, clinical vulnerability, and greater health engagement [<xref rid="B33-vaccines-13-00965" ref-type="bibr">33</xref>,<xref rid="B59-vaccines-13-00965" ref-type="bibr">59</xref>]. Age differences between groups limited control for confounding factors, making it difficult to separate age effects from group-specific effects. Future work should include a larger sample size in the three parallel cohorts. Extended follow-up periods are also necessary to evaluate long-term immune responses and to examine the effects of different vaccination schedules. Despite these challenges, the study population was demographically diverse in age, sex, and ethnicity, reflecting the broader national context.</p><p>In summary, vaccine platform, immune status, and prior SARS-CoV-2 exposure significantly shape the magnitude and cross-reactivity of humoral responses. mRNA vaccines provided the most robust and durable immunity, especially in vulnerable groups [<xref rid="B29-vaccines-13-00965" ref-type="bibr">29</xref>]. Our findings support incorporating non-spike antigens&#8212;such as nucleocapsid and conserved S2 domains&#8212;into future vaccine designs to broaden protection against variants and related coronaviruses [<xref rid="B30-vaccines-13-00965" ref-type="bibr">30</xref>,<xref rid="B34-vaccines-13-00965" ref-type="bibr">34</xref>,<xref rid="B45-vaccines-13-00965" ref-type="bibr">45</xref>,<xref rid="B52-vaccines-13-00965" ref-type="bibr">52</xref>,<xref rid="B53-vaccines-13-00965" ref-type="bibr">53</xref>]. These results have key implications for vaccine policy and immune monitoring. Immune responses vary widely by host factors and prior HCoVs exposure, with OC43 priming spike-specific responses in healthy individuals. In contrast, immunocompromised groups (HD, TR) show weaker responses, highlighting the need for tailored strategies, including additional doses or adjuvanted vaccines. Modest HCoV antibody boosts post-vaccination suggest cross-reactivity should inform both surveillance efforts and the design of pan-coronavirus vaccines.</p></sec><sec sec-type="conclusions" id="sec5-vaccines-13-00965"><title>5. Conclusions</title><p>This study provides evidence for limited but measurable cross-reactivity between SARS-CoV-2 and endemic human coronaviruses (HCoVs), particularly <inline-formula><mml:math id="mm38" overflow="scroll"><mml:mrow><mml:mi>&#946;</mml:mi></mml:mrow></mml:math></inline-formula>-coronavirus OC43. Cross-reactive anti-S IgG responses were most evident in healthy individuals with prior HCoVs exposure, suggesting that pre-existing immunity may modestly enhance vaccine-induced responses through immunological priming. Post-vaccination increases in HCoV-specific antibodies, while modest, further support the presence of antigenic overlap, with implications for immune surveillance and serological interpretation. Reactivity and fluctuations in anti-N IgG responses&#8212;especially after CoronaVac, which induces and boosts these antibodies&#8212;highlight the need for alternative markers of infection that are unaffected by vaccination. By integrating multi-level mixed modeling (MLMM), this study identified key immunological and clinical co-factors that shape antibody responses, reinforcing the relevance of host immune history in vaccine response profiling. These findings emphasize the potential, yet constrained, role of HCoVs cross-reactivity in SARS-CoV-2 immunity and support the rationale for developing broadly protective, pan-coronavirus vaccine platforms.</p></sec></body><back><ack><title>Acknowledgments</title><p>We gratefully acknowledge the Instituto Nacional de Coordinaci&#243;n de Trasplante (INCORT), particularly Fernando Morales Billini and Cesar Zorrilla, for their invaluable support. We also thank the Study Team, Administrative Team, and the National Network of Hospitals for their essential contributions to this research.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-vaccines-13-00965"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.mdpi.com/article/10.3390/vaccines13090965/s1">https://www.mdpi.com/article/10.3390/vaccines13090965/s1</uri>, Supplementary Table S1. End-stage kidney disease and transplant cohort characteristics. Supplementary Table S2. Hemodialysis characteristics. Supplementary Table S3. Transplant characteristics. Supplementary Figure S1. Correlations of Anti-Spike IgG SARS-CoV-2 and HCoVs. Supplementary Figure S2. Correlations of Anti-Nucleocapsid IgG SARS-CoV-2 and HCoVs. Supplementary Figure S3. Multivariate Linear Modeling Performance and Antibody Analysis. Reference [<xref rid="B23-vaccines-13-00965" ref-type="bibr">23</xref>] is cited in the Supplementary materials.</p><supplementary-material id="vaccines-13-00965-s001" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="vaccines-13-00965-s001.zip" position="float" orientation="portrait"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, L.A.S., M.S.Z., K.F. and S.D.; methodology, M.S.Z., S.P.H., D.L. and K.F.; software, L.A.S. and D.L.; validation, L.A.S. and D.L.; formal analysis, L.A.S. and D.L.; investigation, L.A.S., S.M.K., Q.Z., E.A.G. and S.P.H.; resources, M.S.Z.; data curation, L.A.S. and D.L.; writing&#8212;original draft preparation, L.A.S.; writing&#8212;review and editing, M.S.Z., K.F., E.A.G. and S.D.; visualization, L.A.S., D.L. and M.S.Z.; supervision, K.F., M.S.Z. and S.D.; funding acquisition, M.S.Z. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>This is a secondary analysis of existing capillary blood samples and deidentified data previously obtained by the INCORT in the Dominican Republic. The parent study was conducted in accordance with the Declaration of Helsinki, and previously approved by the National Health Bioethics Committee of the Dominican Republic (CONABIOS, the Spanish acronym) (INCORT.PI2020.004.01) for studies involving humans. The secondary analysis was approved by the Institutional Review Boards (IRB) at the University of Rochester Medical Center (IRB STUDY00006807). All research data were coded in compliance with the Department of Health and Human Services Regulations for the Protection of Human Subjects (45 CFR 46.101(b) (4)).</p></notes><notes><title>Informed Consent Statement</title><p>This research study involves a secondary analysis of existing capillary blood samples and deidentified data that were originally collected by the INCORT in the Dominican Republic. The initial research adhered to the Declaration of Helsinki and received approval from the National Health Bioethics Committee of the Dominican Republic (CONABIOS) under protocol INCORT.PI2020.004.01 for studies involving human subjects.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The original data presented in this study, along with the R code used for analysis, are openly available on FigShare. The R code is accessible at DOI: 10.60593/ur.d.29425199, and the dataset is available at DOI: 10.60593/ur.d.29425202.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.</p></notes><glossary><title>Abbreviations</title><p>The following abbreviations are used in this manuscript:
<array orientation="portrait"><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">ACE2</td><td align="left" valign="middle" rowspan="1" colspan="1">Angiotensin-Converting Enzyme 2</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ADE</td><td align="left" valign="middle" rowspan="1" colspan="1">Antibody-dependent enhancement</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CO</td><td align="left" valign="middle" rowspan="1" colspan="1">Control group</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CONABIOS</td><td align="left" valign="middle" rowspan="1" colspan="1">National Health Bioethics Committee of the Dominican Republic (the Spanish acronym)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">COVID-19</td><td align="left" valign="middle" rowspan="1" colspan="1">Coronavirus disease 2019</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DOAJ</td><td align="left" valign="middle" rowspan="1" colspan="1">Directory of Open Access Journals</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ESRD</td><td align="left" valign="middle" rowspan="1" colspan="1">End-stage renal disease</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HCoVs</td><td align="left" valign="middle" rowspan="1" colspan="1">Common Human Coronaviruses</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HD</td><td align="left" valign="middle" rowspan="1" colspan="1">Hemodialysis Patients</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Hgb</td><td align="left" valign="middle" rowspan="1" colspan="1">Hemoglobin</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IgG</td><td align="left" valign="middle" rowspan="1" colspan="1">Immunoglobin G</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">INCORT</td><td align="left" valign="middle" rowspan="1" colspan="1">Instituto Nacional de Coordinaci&#243;n de Trasplante</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IRB</td><td align="left" valign="middle" rowspan="1" colspan="1">Institutional Review Boards</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MDPI</td><td align="left" valign="middle" rowspan="1" colspan="1">Multidisciplinary Digital Publishing Institute</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MDS</td><td align="left" valign="middle" rowspan="1" colspan="1">Multidimensional Scaling</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MLMM</td><td align="left" valign="middle" rowspan="1" colspan="1">Multivariate Linear Mixed Models</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">mPlex-CoV</td><td align="left" valign="middle" rowspan="1" colspan="1">Fluorescent Multiplex Assay</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">N</td><td align="left" valign="middle" rowspan="1" colspan="1">Nucleocapsid</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PCR</td><td align="left" valign="middle" rowspan="1" colspan="1">Polymerase Chain Reaction</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">RNA</td><td align="left" valign="middle" rowspan="1" colspan="1">Ribonucleic acid</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">S</td><td align="left" valign="middle" rowspan="1" colspan="1">Spike</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SARS-CoV-2</td><td align="left" valign="middle" rowspan="1" colspan="1">Severe Acute Respiratory Syndrome coronavirus 2</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TR</td><td align="left" valign="middle" rowspan="1" colspan="1">Transplant Recipients</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">VAMS</td><td align="left" valign="middle" rowspan="1" colspan="1">Volumetric Micro Sampling</td></tr></tbody></array></p></glossary><ref-list><title>References</title><ref id="B1-vaccines-13-00965"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carr</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Kronbichler</surname><given-names>A.</given-names></name><name name-style="western"><surname>Graham-Brown</surname><given-names>M.</given-names></name><name name-style="western"><surname>Abra</surname><given-names>G.</given-names></name><name name-style="western"><surname>Argyropoulos</surname><given-names>C.</given-names></name><name name-style="western"><surname>Harper</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lerma</surname><given-names>E.V.</given-names></name><name name-style="western"><surname>Suri</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Topf</surname><given-names>J.</given-names></name><name name-style="western"><surname>Willicombe</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Systematic Review of Early Immune Response to SARS-CoV-2 Vaccination Among Patients with Chronic Kidney Disease</article-title><source>Kidney Int. Rep.</source><year>2021</year><volume>6</volume><fpage>2292</fpage><lpage>2304</lpage><pub-id pub-id-type="doi">10.1016/j.ekir.2021.06.027</pub-id><pub-id pub-id-type="pmid">34250319</pub-id><pub-id pub-id-type="pmcid">PMC8257418</pub-id></element-citation></ref><ref id="B2-vaccines-13-00965"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grobben</surname><given-names>M.</given-names></name><name name-style="western"><surname>van der Straten</surname><given-names>K.</given-names></name><name name-style="western"><surname>Brouwer</surname><given-names>P.J.M.</given-names></name><name name-style="western"><surname>Brinkkemper</surname><given-names>M.</given-names></name><name name-style="western"><surname>Maisonnasse</surname><given-names>P.</given-names></name><name name-style="western"><surname>Dereuddre-Bosquet</surname><given-names>N.</given-names></name><name name-style="western"><surname>Appelman</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lavell</surname><given-names>A.H.A.</given-names></name><name name-style="western"><surname>van Vught</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Burger</surname><given-names>J.A.</given-names></name><etal/></person-group><article-title>Cross-reactive antibodies after SARS-CoV-2 infection and vaccination</article-title><source>eLife</source><year>2021</year><volume>10</volume><fpage>e70330</fpage><pub-id pub-id-type="doi">10.7554/eLife.70330</pub-id><pub-id pub-id-type="pmid">34812143</pub-id><pub-id pub-id-type="pmcid">PMC8610423</pub-id></element-citation></ref><ref id="B3-vaccines-13-00965"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jeong</surname><given-names>A.Y.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>D.J.</given-names></name></person-group><article-title>Pre-existing Immunity to Endemic Human Coronaviruses Does Not Affect the Immune Response to SARS-CoV-2 Spike in a Murine Vaccination Model</article-title><source>Immune Netw.</source><year>2023</year><volume>23</volume><fpage>e19</fpage><pub-id pub-id-type="doi">10.4110/in.2023.23.e19</pub-id><pub-id pub-id-type="pmid">37179748</pub-id><pub-id pub-id-type="pmcid">PMC10166660</pub-id></element-citation></ref><ref id="B4-vaccines-13-00965"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bennett</surname><given-names>T.D.</given-names></name><name name-style="western"><surname>Moffitt</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Hajagos</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Amor</surname><given-names>B.</given-names></name><name name-style="western"><surname>Anand</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bissell</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Bradwell</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Bremer</surname><given-names>C.</given-names></name><name name-style="western"><surname>Byrd</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Denham</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Clinical Characterization and Prediction of Clinical Severity of SARS-CoV-2 Infection Among US Adults Using Data From the US National COVID Cohort Collaborative</article-title><source>JAMA Netw. Open</source><year>2021</year><volume>4</volume><fpage>e2116901</fpage><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2021.16901</pub-id><pub-id pub-id-type="pmid">34255046</pub-id><pub-id pub-id-type="pmcid">PMC8278272</pub-id></element-citation></ref><ref id="B5-vaccines-13-00965"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pecora</surname><given-names>N.D.</given-names></name><name name-style="western"><surname>Zand</surname><given-names>M.S.</given-names></name></person-group><article-title>Measuring the Serologic Response to Severe Acute Respiratory Syndrome Coronavirus 2: Methods and Meaning</article-title><source>Clin. Lab. Med.</source><year>2020</year><volume>40</volume><fpage>603</fpage><lpage>614</lpage><pub-id pub-id-type="doi">10.1016/j.cll.2020.08.014</pub-id><pub-id pub-id-type="pmid">33121625</pub-id><pub-id pub-id-type="pmcid">PMC7414299</pub-id></element-citation></ref><ref id="B6-vaccines-13-00965"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wiltse</surname><given-names>A.</given-names></name><name name-style="western"><surname>Emo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hilchey</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Zand</surname><given-names>M.S.</given-names></name></person-group><article-title>Application of volumetric absorptive microsampling (VAMS) to measure multidimensional anti-influenza IgG antibodies by the mPlex-Flu assay</article-title><source>J. Clin. Transl. Sci.</source><year>2019</year><volume>3</volume><fpage>332</fpage><lpage>343</lpage><pub-id pub-id-type="doi">10.1017/cts.2019.410</pub-id><pub-id pub-id-type="pmid">31827907</pub-id><pub-id pub-id-type="pmcid">PMC6885997</pub-id></element-citation></ref><ref id="B7-vaccines-13-00965"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beretta</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cranage</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zipeto</surname><given-names>D.</given-names></name></person-group><article-title>Is Cross-Reactive Immunity Triggering COVID-19 Immunopathogenesis?</article-title><source>Front. Immunol.</source><year>2020</year><volume>11</volume><elocation-id>567710</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2020.567710</pub-id><pub-id pub-id-type="pmid">33178193</pub-id><pub-id pub-id-type="pmcid">PMC7594548</pub-id></element-citation></ref><ref id="B8-vaccines-13-00965"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wiltse</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zand</surname><given-names>M.S.</given-names></name></person-group><article-title>Antibody Mediated Immunity to SARS-CoV-2 and Human Coronaviruses: Multiplex Beads Assay and Volumetric Absorptive Microsampling to Generate Immune Repertoire Cartography</article-title><source>Front. Immunol.</source><year>2021</year><volume>12</volume><elocation-id>696370</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2021.696370</pub-id><pub-id pub-id-type="pmid">34386006</pub-id><pub-id pub-id-type="pmcid">PMC8353270</pub-id></element-citation></ref><ref id="B9-vaccines-13-00965"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>G.F.</given-names></name></person-group><article-title>Humoral and cellular immunity and the safety of COVID-19 vaccines: A summary of data published by 21 May 2021</article-title><source>Int. Immunol.</source><year>2021</year><volume>33</volume><fpage>529</fpage><lpage>540</lpage><pub-id pub-id-type="doi">10.1093/intimm/dxab061</pub-id><pub-id pub-id-type="pmid">34491327</pub-id><pub-id pub-id-type="pmcid">PMC8499872</pub-id></element-citation></ref><ref id="B10-vaccines-13-00965"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bates</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Weinstein</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Farley</surname><given-names>S.</given-names></name><name name-style="western"><surname>Leier</surname><given-names>H.C.</given-names></name><name name-style="western"><surname>Messer</surname><given-names>W.B.</given-names></name><name name-style="western"><surname>Tafesse</surname><given-names>F.G.</given-names></name></person-group><article-title>Cross-reactivity of SARS-CoV structural protein antibodies against SARS-CoV-2</article-title><source>Cell Rep.</source><year>2021</year><volume>34</volume><fpage>108737</fpage><pub-id pub-id-type="doi">10.1016/j.celrep.2021.108737</pub-id><pub-id pub-id-type="pmid">33545052</pub-id><pub-id pub-id-type="pmcid">PMC7835103</pub-id></element-citation></ref><ref id="B11-vaccines-13-00965"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Melin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Svensson</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Albinsson</surname><given-names>B.</given-names></name><name name-style="western"><surname>Winqvist</surname><given-names>O.</given-names></name><name name-style="western"><surname>Pauksens</surname><given-names>K.</given-names></name></person-group><article-title>Humoral and cellular response to SARS-CoV-2 BNT162b2 mRNA vaccine in hemodialysis patients</article-title><source>BMC Immunol.</source><year>2021</year><volume>22</volume><elocation-id>70</elocation-id><pub-id pub-id-type="doi">10.1186/s12865-021-00458-0</pub-id><pub-id pub-id-type="pmid">34666683</pub-id><pub-id pub-id-type="pmcid">PMC8524400</pub-id></element-citation></ref><ref id="B12-vaccines-13-00965"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Asamoah-Boaheng</surname><given-names>M.</given-names></name><name name-style="western"><surname>Grunau</surname><given-names>B.</given-names></name><name name-style="western"><surname>Karim</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Jassem</surname><given-names>A.N.</given-names></name><name name-style="western"><surname>Bolster</surname><given-names>J.</given-names></name><name name-style="western"><surname>Marquez</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Scheuermeyer</surname><given-names>F.X.</given-names></name><name name-style="western"><surname>Goldfarb</surname><given-names>D.M.</given-names></name></person-group><article-title>Are higher antibody levels against seasonal human coronaviruses associated with a more robust humoral immune response after SARS-CoV-2 vaccination?</article-title><source>Front. Immunol.</source><year>2022</year><volume>13</volume><elocation-id>954093</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2022.954093</pub-id><pub-id pub-id-type="pmid">36159791</pub-id><pub-id pub-id-type="pmcid">PMC9493031</pub-id></element-citation></ref><ref id="B13-vaccines-13-00965"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pinotti</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wikramaratna</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Obolski</surname><given-names>U.</given-names></name><name name-style="western"><surname>Paton</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Damineli</surname><given-names>D.S.C.</given-names></name><name name-style="western"><surname>Alcantara</surname><given-names>L.C.J.</given-names></name><name name-style="western"><surname>Giovanetti</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>S.</given-names></name><name name-style="western"><surname>Louren&#231;o</surname><given-names>J.</given-names></name></person-group><article-title>Potential impact of individual exposure histories to endemic human coronaviruses on age-dependent severity of COVID-19</article-title><source>BMC Med.</source><year>2021</year><volume>19</volume><elocation-id>19</elocation-id><pub-id pub-id-type="doi">10.1186/s12916-020-01887-1</pub-id><pub-id pub-id-type="pmid">33430856</pub-id><pub-id pub-id-type="pmcid">PMC7801230</pub-id></element-citation></ref><ref id="B14-vaccines-13-00965"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Windpessl</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bruchfeld</surname><given-names>A.</given-names></name><name name-style="western"><surname>Anders</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Kramer</surname><given-names>H.</given-names></name><name name-style="western"><surname>Waldman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Renia</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ng</surname><given-names>L.F.P.</given-names></name><name name-style="western"><surname>Xing</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Kronbichler</surname><given-names>A.</given-names></name></person-group><article-title>COVID-19 vaccines and kidney disease</article-title><source>Nat. Rev. Nephrol.</source><year>2021</year><volume>17</volume><fpage>291</fpage><lpage>293</lpage><pub-id pub-id-type="doi">10.1038/s41581-021-00406-6</pub-id><pub-id pub-id-type="pmid">33558753</pub-id><pub-id pub-id-type="pmcid">PMC7869766</pub-id></element-citation></ref><ref id="B15-vaccines-13-00965"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Samaan</surname><given-names>E.</given-names></name><name name-style="western"><surname>Elmaria</surname><given-names>M.O.</given-names></name><name name-style="western"><surname>Khedr</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gaber</surname><given-names>T.</given-names></name><name name-style="western"><surname>Elsayed</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Shenouda</surname><given-names>R.N.</given-names></name><name name-style="western"><surname>Gamal</surname><given-names>H.</given-names></name><name name-style="western"><surname>Shahin</surname><given-names>D.</given-names></name><name name-style="western"><surname>Abousamra</surname><given-names>N.K.</given-names></name><name name-style="western"><surname>Shemies</surname><given-names>R.</given-names></name></person-group><article-title>Characterization of regulatory T cells in SARS-CoV-2 infected hemodialysis patients: Relation to clinical and radiological severity</article-title><source>BMC Nephrol.</source><year>2022</year><volume>23</volume><elocation-id>391</elocation-id><pub-id pub-id-type="doi">10.1186/s12882-022-03024-x</pub-id><pub-id pub-id-type="pmid">36476424</pub-id><pub-id pub-id-type="pmcid">PMC9730673</pub-id></element-citation></ref><ref id="B16-vaccines-13-00965"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ng</surname><given-names>K.W.</given-names></name><name name-style="western"><surname>Faulkner</surname><given-names>N.</given-names></name><name name-style="western"><surname>Cornish</surname><given-names>G.H.</given-names></name><name name-style="western"><surname>Rosa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Harvey</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hussain</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ulferts</surname><given-names>R.</given-names></name><name name-style="western"><surname>Earl</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wrobel</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Benton</surname><given-names>D.J.</given-names></name><etal/></person-group><article-title>Preexisting and de novo humoral immunity to SARS-CoV-2 in humans</article-title><source>Science</source><year>2020</year><volume>370</volume><fpage>1339</fpage><lpage>1343</lpage><pub-id pub-id-type="doi">10.1126/science.abe1107</pub-id><pub-id pub-id-type="pmid">33159009</pub-id><pub-id pub-id-type="pmcid">PMC7857411</pub-id></element-citation></ref><ref id="B17-vaccines-13-00965"><label>17.</label><element-citation publication-type="other"><person-group person-group-type="author"><name name-style="western"><surname>Fernandez</surname><given-names>C.</given-names></name></person-group><article-title>En Rep&#250;blica Dominicana, 5275 Pacientes Reciben Hemodi&#225;lisis y 500 Esperan un Ri&#241;&#243;n</article-title><source>Diario Libre</source><day>10</day><month>March</month><year>2023</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.diariolibre.com/actualidad/salud/2023/03/10/en-rd-5275-reciben-hemodialisis-y-500-esperan-un-rinon/2250175" ext-link-type="uri">https://www.diariolibre.com/actualidad/salud/2023/03/10/en-rd-5275-reciben-hemodialisis-y-500-esperan-un-rinon/2250175</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-06-05">(accessed on 5 June 2025)</date-in-citation></element-citation></ref><ref id="B18-vaccines-13-00965"><label>18.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Instituto Nacional de Coordinaci&#243;n de Trasplante (INCORT)</collab></person-group><source>Trasplantes de &#211;rganos y Tejidos de la Rep&#250;blica Dominicana 2008&#8211;2023 Report</source><publisher-name>INCORT</publisher-name><publisher-loc>Santo Domingo, Dominican Republic</publisher-loc><year>2024</year></element-citation></ref><ref id="B19-vaccines-13-00965"><label>19.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Ministerio de Salud P&#250;blica de La Rep&#250;blica Dominicana</collab></person-group><source>Gobierno Presenta Plan Nacional de Vacunaci&#243;n Contra COVID-19</source><publisher-name>Ministerio de Salud P&#250;blica de La Rep&#250;blica Dominicana</publisher-name><publisher-loc>Santo Domingo, Dominican Republic</publisher-loc><year>2021</year></element-citation></ref><ref id="B20-vaccines-13-00965"><label>20.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>Dominican Today</collab></person-group><article-title>Vaccines that the Dominican Republic Will Use Are Very Effective, 13 February 2021</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://dominicantoday.com/dr/health/2021/02/13/vaccines-that-the-country-will-use-are-very-effective/" ext-link-type="uri">https://dominicantoday.com/dr/health/2021/02/13/vaccines-that-the-country-will-use-are-very-effective/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-06-02">(accessed on 2 June 2025)</date-in-citation></element-citation></ref><ref id="B21-vaccines-13-00965"><label>21.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><article-title>WHO Caronavirus Dashboard</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://covid19.who.int/" ext-link-type="uri">https://covid19.who.int/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-06-10">(accessed on 10 June 2025)</date-in-citation></element-citation></ref><ref id="B22-vaccines-13-00965"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cameron</surname><given-names>A.</given-names></name><name name-style="western"><surname>Porterfield</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Byron</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pearson</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Bohrhunter</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Cardillo</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Ryan-Muntz</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sorensen</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Caserta</surname><given-names>M.</given-names></name><etal/></person-group><article-title>A Multiplex Microsphere IgG Assay for SARS-CoV-2 Using ACE2-Mediated Inhibition as a Surrogate for Neutralization</article-title><source>J. Clin. Microbiol.</source><year>2021</year><volume>59</volume><fpage>10-1128</fpage><pub-id pub-id-type="doi">10.1128/JCM.02489-20</pub-id><pub-id pub-id-type="pmcid">PMC8111159</pub-id><pub-id pub-id-type="pmid">33139422</pub-id></element-citation></ref><ref id="B23-vaccines-13-00965"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alcantara Sanchez</surname><given-names>L.</given-names></name><name name-style="western"><surname>Alvarez Guerra</surname><given-names>E.</given-names></name><name name-style="western"><surname>Li</surname><given-names>D.</given-names></name><name name-style="western"><surname>King</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Hilchey</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Dewhurst</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fiscella</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zand</surname><given-names>M.S.</given-names></name></person-group><article-title>Antibody Response to SARS-CoV-2 Vaccines in Transplant Recipients and Hemodialysis Patients: Data from the Dominican Republic</article-title><source>Vaccines</source><year>2024</year><volume>12</volume><elocation-id>1312</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines12121312</pub-id><pub-id pub-id-type="pmid">39771974</pub-id><pub-id pub-id-type="pmcid">PMC11680170</pub-id></element-citation></ref><ref id="B24-vaccines-13-00965"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kompaniyets</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pennington</surname><given-names>A.F.</given-names></name><name name-style="western"><surname>Goodman</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Rosenblum</surname><given-names>H.G.</given-names></name><name name-style="western"><surname>Belay</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ko</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Chevinsky</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Schieber</surname><given-names>L.Z.</given-names></name><name name-style="western"><surname>Summers</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Lavery</surname><given-names>A.M.</given-names></name><etal/></person-group><article-title>Underlying Medical Conditions and Severe Illness Among 540,667 Adults Hospitalized with COVID-19, March 2020&#8211;March 2021</article-title><source>Prev. Chronic Dis.</source><year>2021</year><volume>18</volume><fpage>E66</fpage><pub-id pub-id-type="doi">10.5888/pcd18.210123</pub-id><pub-id pub-id-type="pmid">34197283</pub-id><pub-id pub-id-type="pmcid">PMC8269743</pub-id></element-citation></ref><ref id="B25-vaccines-13-00965"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name></person-group><article-title>Analysis of classical multidimensional scaling: Clustering, dimension reduction, and visualization</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2023</year><volume>120</volume><fpage>e2211300120</fpage></element-citation></ref><ref id="B26-vaccines-13-00965"><label>26.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>United Nations Population Fund (UNFPA)</collab></person-group><source>Encuesta Nacional de Autopercepci&#243;n Racial y &#201;tnica en Rep&#250;blica Dominicana</source><publisher-name>UNFPA</publisher-name><publisher-loc>New York, NY, USA</publisher-loc><year>2022</year></element-citation></ref><ref id="B27-vaccines-13-00965"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Montinaro</surname><given-names>F.</given-names></name><name name-style="western"><surname>Busby</surname><given-names>G.B.</given-names></name><name name-style="western"><surname>Pascali</surname><given-names>V.L.</given-names></name><name name-style="western"><surname>Myers</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hellenthal</surname><given-names>G.</given-names></name><name name-style="western"><surname>Capelli</surname><given-names>C.</given-names></name></person-group><article-title>Unravelling the hidden ancestry of American admixed populations</article-title><source>Nat. Commun.</source><year>2015</year><volume>6</volume><fpage>6596</fpage><pub-id pub-id-type="doi">10.1038/ncomms7596</pub-id><pub-id pub-id-type="pmid">25803618</pub-id><pub-id pub-id-type="pmcid">PMC4374169</pub-id></element-citation></ref><ref id="B28-vaccines-13-00965"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Banham</surname><given-names>G.D.</given-names></name><name name-style="western"><surname>Godlee</surname><given-names>A.</given-names></name><name name-style="western"><surname>Faustini</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Cunningham</surname><given-names>A.F.</given-names></name><name name-style="western"><surname>Richter</surname><given-names>A.</given-names></name><name name-style="western"><surname>Harper</surname><given-names>L.</given-names></name><collab>on behalf of the COVID-HD Birmingham Study Group</collab></person-group><article-title>Hemodialysis Patients Make Long-Lived Antibodies against SARS-CoV-2 that May Be Associated with Reduced Reinfection</article-title><source>J. Am. Soc. Nephrol.</source><year>2021</year><volume>32</volume><fpage>2140</fpage><lpage>2142</lpage><pub-id pub-id-type="doi">10.1681/ASN.2021020188</pub-id><pub-id pub-id-type="pmid">34341181</pub-id><pub-id pub-id-type="pmcid">PMC8729838</pub-id></element-citation></ref><ref id="B29-vaccines-13-00965"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goel</surname><given-names>R.R.</given-names></name><name name-style="western"><surname>Apostolidis</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Painter</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Mathew</surname><given-names>D.</given-names></name><name name-style="western"><surname>Pattekar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kuthuru</surname><given-names>O.</given-names></name><name name-style="western"><surname>Gouma</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hicks</surname><given-names>P.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>W.</given-names></name><name name-style="western"><surname>Rosenfeld</surname><given-names>A.M.</given-names></name><etal/></person-group><article-title>mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern</article-title><source>Science</source><year>2021</year><volume>374</volume><fpage>abm0829</fpage><pub-id pub-id-type="doi">10.1126/science.abm0829</pub-id><pub-id pub-id-type="pmid">34648302</pub-id><pub-id pub-id-type="pmcid">PMC9284784</pub-id></element-citation></ref><ref id="B30-vaccines-13-00965"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reynolds</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Gibbons</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Pade</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Sandoval</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Pieper</surname><given-names>F.</given-names></name><name name-style="western"><surname>Butler</surname><given-names>D.K.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Otter</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Boyton</surname><given-names>R.J.</given-names></name><etal/></person-group><article-title>Heterologous infection and vaccination shapes immunity against SARS-CoV-2 variants</article-title><source>Science</source><year>2022</year><volume>375</volume><fpage>183</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1126/science.abm0811</pub-id><pub-id pub-id-type="pmid">34855510</pub-id><pub-id pub-id-type="pmcid">PMC10186585</pub-id></element-citation></ref><ref id="B31-vaccines-13-00965"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amirthalingam</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bernal</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Andrews</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Whitaker</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gower</surname><given-names>C.</given-names></name><name name-style="western"><surname>Stowe</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tessier</surname><given-names>E.</given-names></name><name name-style="western"><surname>Subbarao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ireland</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ramsay</surname><given-names>M.E.</given-names></name><etal/></person-group><article-title>Serological responses and vaccine effectiveness for extended COVID-19 vaccine schedules in England</article-title><source>Nat. Commun.</source><year>2021</year><volume>12</volume><fpage>7217</fpage><pub-id pub-id-type="doi">10.1038/s41467-021-27410-5</pub-id><pub-id pub-id-type="pmid">34893611</pub-id><pub-id pub-id-type="pmcid">PMC8664823</pub-id></element-citation></ref><ref id="B32-vaccines-13-00965"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ziemba</surname><given-names>R.</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>K.N.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>T.H.</given-names></name><name name-style="western"><surname>Schaeffer</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Mayo</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>McGann</surname><given-names>P.</given-names></name><name name-style="western"><surname>Quinn</surname><given-names>S.</given-names></name><name name-style="western"><surname>Roach</surname><given-names>J.</given-names></name><name name-style="western"><surname>Huff</surname><given-names>E.D.</given-names></name></person-group><article-title>Excess Death Estimates in Patients with End-Stage Renal Disease&#8212;United States, February&#8211;August 2020</article-title><source>MMWR Morb. Mortal. Wkly. Rep.</source><year>2021</year><volume>70</volume><fpage>825</fpage><lpage>829</lpage><pub-id pub-id-type="doi">10.15585/mmwr.mm7022e2</pub-id><pub-id pub-id-type="pmid">34081687</pub-id><pub-id pub-id-type="pmcid">PMC8174675</pub-id></element-citation></ref><ref id="B33-vaccines-13-00965"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benotmane</surname><given-names>I.</given-names></name><name name-style="western"><surname>Gautier</surname><given-names>G.</given-names></name><name name-style="western"><surname>Perrin</surname><given-names>P.</given-names></name><name name-style="western"><surname>Olagne</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cognard</surname><given-names>N.</given-names></name><name name-style="western"><surname>Fafi-Kremer</surname><given-names>S.</given-names></name><name name-style="western"><surname>Caillard</surname><given-names>S.</given-names></name></person-group><article-title>Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients with Minimal Serologic Response to 2 Doses</article-title><source>JAMA</source><year>2021</year><volume>326</volume><fpage>1063</fpage><lpage>1065</lpage><pub-id pub-id-type="doi">10.1001/jama.2021.12339</pub-id><pub-id pub-id-type="pmid">34297036</pub-id><pub-id pub-id-type="pmcid">PMC8456389</pub-id></element-citation></ref><ref id="B34-vaccines-13-00965"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sette</surname><given-names>A.</given-names></name><name name-style="western"><surname>Crotty</surname><given-names>S.</given-names></name></person-group><article-title>Adaptive immunity to SARS-CoV-2 and COVID-19</article-title><source>Cell</source><year>2021</year><volume>184</volume><fpage>861</fpage><lpage>880</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2021.01.007</pub-id><pub-id pub-id-type="pmid">33497610</pub-id><pub-id pub-id-type="pmcid">PMC7803150</pub-id></element-citation></ref><ref id="B35-vaccines-13-00965"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anderson</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Goodwin</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Verma</surname><given-names>A.</given-names></name><name name-style="western"><surname>Arevalo</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Bolton</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Weirick</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Gouma</surname><given-names>S.</given-names></name><name name-style="western"><surname>McAllister</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Christensen</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Eller</surname><given-names>M.A.</given-names></name><etal/></person-group><article-title>SARS-CoV-2 mRNA vaccines induce broad antibody responses including cross-reactivity to seasonal coronaviruses</article-title><source>Cell</source><year>2021</year><volume>184</volume><fpage>1234</fpage><lpage>1242.e9</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2021.02.033</pub-id></element-citation></ref><ref id="B36-vaccines-13-00965"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>G.</given-names></name></person-group><article-title>Immune Dysfunction in Uremia 2020</article-title><source>Toxins</source><year>2020</year><volume>12</volume><elocation-id>439</elocation-id><pub-id pub-id-type="doi">10.3390/toxins12070439</pub-id><pub-id pub-id-type="pmid">32635646</pub-id><pub-id pub-id-type="pmcid">PMC7404977</pub-id></element-citation></ref><ref id="B37-vaccines-13-00965"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aydillo</surname><given-names>T.</given-names></name><name name-style="western"><surname>Rombauts</surname><given-names>A.</given-names></name><name name-style="western"><surname>Stadlbauer</surname><given-names>D.</given-names></name><name name-style="western"><surname>Aslam</surname><given-names>S.</given-names></name><name name-style="western"><surname>Abelenda-Alonso</surname><given-names>G.</given-names></name><name name-style="western"><surname>Escalera</surname><given-names>A.</given-names></name><name name-style="western"><surname>Amanat</surname><given-names>F.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Krammer</surname><given-names>F.</given-names></name><name name-style="western"><surname>Garcia-Sastre</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Immunological imprinting of the antibody response in COVID-19 patients</article-title><source>Nat. Commun.</source><year>2021</year><volume>12</volume><fpage>3781</fpage><pub-id pub-id-type="doi">10.1038/s41467-021-23977-1</pub-id><pub-id pub-id-type="pmid">34145263</pub-id><pub-id pub-id-type="pmcid">PMC8213790</pub-id></element-citation></ref><ref id="B38-vaccines-13-00965"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garziano</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cano Fiestas</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vanetti</surname><given-names>C.</given-names></name><name name-style="western"><surname>Strizzi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Murno</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Clerici</surname><given-names>M.</given-names></name><name name-style="western"><surname>Biasin</surname><given-names>M.</given-names></name></person-group><article-title>SARS-CoV-2 natural infection, but not vaccine-induced immunity, elicits cross-reactive immunity to OC43</article-title><source>Heliyon</source><year>2024</year><volume>10</volume><fpage>e37928</fpage><pub-id pub-id-type="doi">10.1016/j.heliyon.2024.e37928</pub-id><pub-id pub-id-type="pmid">39391514</pub-id><pub-id pub-id-type="pmcid">PMC11466580</pub-id></element-citation></ref><ref id="B39-vaccines-13-00965"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boyarsky</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Werbel</surname><given-names>W.A.</given-names></name><name name-style="western"><surname>Avery</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Tobian</surname><given-names>A.A.R.</given-names></name><name name-style="western"><surname>Massie</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Segev</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Garonzik-Wang</surname><given-names>J.M.</given-names></name></person-group><article-title>Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients</article-title><source>JAMA</source><year>2021</year><volume>325</volume><fpage>1784</fpage><lpage>1786</lpage><pub-id pub-id-type="doi">10.1001/jama.2021.4385</pub-id><pub-id pub-id-type="pmid">33720292</pub-id><pub-id pub-id-type="pmcid">PMC7961463</pub-id></element-citation></ref><ref id="B40-vaccines-13-00965"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kamar</surname><given-names>N.</given-names></name><name name-style="western"><surname>Abravanel</surname><given-names>F.</given-names></name><name name-style="western"><surname>Marion</surname><given-names>O.</given-names></name><name name-style="western"><surname>Couat</surname><given-names>C.</given-names></name><name name-style="western"><surname>Izopet</surname><given-names>J.</given-names></name><name name-style="western"><surname>Del Bello</surname><given-names>A.</given-names></name></person-group><article-title>Three Doses of an mRNA COVID-19 Vaccine in Solid-Organ Transplant Recipients</article-title><source>N. Engl. J. Med.</source><year>2021</year><volume>385</volume><fpage>661</fpage><lpage>662</lpage><pub-id pub-id-type="doi">10.1056/NEJMc2108861</pub-id><pub-id pub-id-type="pmid">34161700</pub-id><pub-id pub-id-type="pmcid">PMC8262620</pub-id></element-citation></ref><ref id="B41-vaccines-13-00965"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shrock</surname><given-names>E.</given-names></name><name name-style="western"><surname>Fujimura</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kula</surname><given-names>T.</given-names></name><name name-style="western"><surname>Timms</surname><given-names>R.T.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>I.H.</given-names></name><name name-style="western"><surname>Leng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Sie</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>M.Z.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity</article-title><source>Science</source><year>2020</year><volume>370</volume><fpage>eabd4250</fpage><pub-id pub-id-type="doi">10.1126/science.abd4250</pub-id><pub-id pub-id-type="pmid">32994364</pub-id><pub-id pub-id-type="pmcid">PMC7857405</pub-id></element-citation></ref><ref id="B42-vaccines-13-00965"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boyarsky</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Werbel</surname><given-names>W.A.</given-names></name><name name-style="western"><surname>Avery</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Tobian</surname><given-names>A.A.R.</given-names></name><name name-style="western"><surname>Massie</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Segev</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Garonzik-Wang</surname><given-names>J.M.</given-names></name></person-group><article-title>Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients</article-title><source>JAMA</source><year>2021</year><volume>325</volume><fpage>2204</fpage><lpage>2206</lpage><pub-id pub-id-type="doi">10.1001/jama.2021.7489</pub-id><pub-id pub-id-type="pmid">33950155</pub-id><pub-id pub-id-type="pmcid">PMC8100911</pub-id></element-citation></ref><ref id="B43-vaccines-13-00965"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ayala-Borges</surname><given-names>B.</given-names></name><name name-style="western"><surname>Escobedo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Egri</surname><given-names>N.</given-names></name><name name-style="western"><surname>Herrera</surname><given-names>S.</given-names></name><name name-style="western"><surname>Crespo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mirabet</surname><given-names>S.</given-names></name><name name-style="western"><surname>Arias-Cabrales</surname><given-names>C.</given-names></name><name name-style="western"><surname>Vilella</surname><given-names>A.</given-names></name><name name-style="western"><surname>Palou</surname><given-names>E.</given-names></name><name name-style="western"><surname>Mosquera</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Impact of SARS-CoV-2 Infection on Humoral and Cellular Immunity in a Cohort of Vaccinated Solid Organ Transplant Recipients</article-title><source>Vaccines</source><year>2023</year><volume>11</volume><elocation-id>1845</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines11121845</pub-id><pub-id pub-id-type="pmid">38140248</pub-id><pub-id pub-id-type="pmcid">PMC10747916</pub-id></element-citation></ref><ref id="B44-vaccines-13-00965"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ekstr&#246;m</surname><given-names>N.</given-names></name><name name-style="western"><surname>Leino</surname><given-names>T.</given-names></name><name name-style="western"><surname>Juutinen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lehtonen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Haveri</surname><given-names>A.</given-names></name><name name-style="western"><surname>Liedes</surname><given-names>O.</given-names></name><name name-style="western"><surname>Vara</surname><given-names>S.</given-names></name><name name-style="western"><surname>Salo</surname><given-names>H.</given-names></name><name name-style="western"><surname>Palmu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nohynek</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Hybrid Immunity Improves the Immune Response after the Fourth COVID-19 Vaccine Dose in Individuals with Medical Conditions Predisposing to Severe COVID-19</article-title><source>Vaccines</source><year>2024</year><volume>12</volume><elocation-id>247</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines12030247</pub-id><pub-id pub-id-type="pmid">38543881</pub-id><pub-id pub-id-type="pmcid">PMC10975123</pub-id></element-citation></ref><ref id="B45-vaccines-13-00965"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Altmann</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Boyton</surname><given-names>R.J.</given-names></name></person-group><article-title>Immunity to SARS-CoV-2 variants of concern</article-title><source>Science</source><year>2021</year><volume>371</volume><fpage>1103</fpage><lpage>1104</lpage><pub-id pub-id-type="doi">10.1126/science.abg7404</pub-id><pub-id pub-id-type="pmid">33707254</pub-id></element-citation></ref><ref id="B46-vaccines-13-00965"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clark</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Clark</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Coscia</surname><given-names>A.</given-names></name><name name-style="western"><surname>McKay</surname><given-names>L.G.A.</given-names></name><name name-style="western"><surname>Shankar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>R.I.</given-names></name><name name-style="western"><surname>Brusic</surname><given-names>V.</given-names></name><name name-style="western"><surname>Balazs</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>R.A.</given-names></name></person-group><article-title>SARS-CoV-2 evolution in an immunocompromised host reveals shared neutralization escape mechanisms</article-title><source>Cell</source><year>2021</year><volume>184</volume><fpage>2605</fpage><lpage>2617.e18</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2021.03.027</pub-id><pub-id pub-id-type="pmid">33831372</pub-id><pub-id pub-id-type="pmcid">PMC7962548</pub-id></element-citation></ref><ref id="B47-vaccines-13-00965"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anand</surname><given-names>S.</given-names></name><name name-style="western"><surname>Montez-Rath</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Han</surname><given-names>J.</given-names></name><name name-style="western"><surname>Garcia</surname><given-names>P.</given-names></name><name name-style="western"><surname>Cadden</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hunsader</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kerschmann</surname><given-names>R.</given-names></name><name name-style="western"><surname>Beyer</surname><given-names>P.</given-names></name><name name-style="western"><surname>Dittrich</surname><given-names>M.</given-names></name><name name-style="western"><surname>Block</surname><given-names>G.A.</given-names></name><etal/></person-group><article-title>Antibody Response to COVID-19 Vaccination in Patients Receiving Dialysis</article-title><source>J. Am. Soc. Nephrol.</source><year>2021</year><volume>32</volume><fpage>2435</fpage><lpage>2438</lpage><pub-id pub-id-type="doi">10.1681/ASN.2021050611</pub-id><pub-id pub-id-type="pmid">34117129</pub-id><pub-id pub-id-type="pmcid">PMC8722791</pub-id></element-citation></ref><ref id="B48-vaccines-13-00965"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sahin</surname><given-names>U.</given-names></name><name name-style="western"><surname>Muik</surname><given-names>A.</given-names></name><name name-style="western"><surname>Derhovanessian</surname><given-names>E.</given-names></name><name name-style="western"><surname>Vogler</surname><given-names>I.</given-names></name><name name-style="western"><surname>Kranz</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Vormehr</surname><given-names>M.</given-names></name><name name-style="western"><surname>Baum</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pascal</surname><given-names>K.</given-names></name><name name-style="western"><surname>Quandt</surname><given-names>J.</given-names></name><name name-style="western"><surname>Maurus</surname><given-names>D.</given-names></name><etal/></person-group><article-title>COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses</article-title><source>Nature</source><year>2020</year><volume>586</volume><fpage>594</fpage><lpage>599</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2814-7</pub-id><pub-id pub-id-type="pmid">32998157</pub-id></element-citation></ref><ref id="B49-vaccines-13-00965"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hall</surname><given-names>V.J.</given-names></name><name name-style="western"><surname>Foulkes</surname><given-names>S.</given-names></name><name name-style="western"><surname>Saei</surname><given-names>A.</given-names></name><name name-style="western"><surname>Andrews</surname><given-names>N.</given-names></name><name name-style="western"><surname>Oguti</surname><given-names>B.</given-names></name><name name-style="western"><surname>Charlett</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wellington</surname><given-names>E.</given-names></name><name name-style="western"><surname>Stowe</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gillson</surname><given-names>N.</given-names></name><name name-style="western"><surname>Atti</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Effectiveness of BNT162b2 mRNA vaccine against infection and COVID-19 vaccine coverage in healthcare workers in England: A test-negative case-control study</article-title><source>Lancet Infect. Dis.</source><year>2021</year><volume>21</volume><fpage>1246</fpage><lpage>1255</lpage></element-citation></ref><ref id="B50-vaccines-13-00965"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stumpf</surname><given-names>J.</given-names></name><name name-style="western"><surname>Siepmann</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lindner</surname><given-names>T.</given-names></name><name name-style="western"><surname>Karger</surname><given-names>C.</given-names></name><name name-style="western"><surname>Schw&#246;bel</surname><given-names>J.</given-names></name><name name-style="western"><surname>Anders</surname><given-names>L.</given-names></name><name name-style="western"><surname>Faulhaber-Walter</surname><given-names>R.</given-names></name><name name-style="western"><surname>Schewe</surname><given-names>J.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>H.</given-names></name><name name-style="western"><surname>Schirutschke</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: A prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine</article-title><source>Lancet Reg. Health&#8212;Europe</source><year>2021</year><volume>9</volume><fpage>100178</fpage><pub-id pub-id-type="doi">10.1016/j.lanepe.2021.100178</pub-id><pub-id pub-id-type="pmid">34318288</pub-id><pub-id pub-id-type="pmcid">PMC8299287</pub-id></element-citation></ref><ref id="B51-vaccines-13-00965"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Narongkiatikhun</surname><given-names>P.</given-names></name><name name-style="western"><surname>Noppakun</surname><given-names>K.</given-names></name><name name-style="western"><surname>Chaiwarith</surname><given-names>R.</given-names></name><name name-style="western"><surname>Winichakoon</surname><given-names>P.</given-names></name><name name-style="western"><surname>Vongsanim</surname><given-names>S.</given-names></name><name name-style="western"><surname>Suteeka</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Pongsuwan</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kusirisin</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wongsarikan</surname><given-names>N.</given-names></name><name name-style="western"><surname>Fanhchaksai</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Immunogenicity and Safety of Homologous and Heterologous Prime-Boost of CoronaVac(<sup>&#174;</sup>) and ChAdOx1 nCoV-19 among Hemodialysis Patients: An Observational Prospective Cohort Study</article-title><source>Vaccines</source><year>2023</year><volume>11</volume><elocation-id>715</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines11040715</pub-id><pub-id pub-id-type="pmid">37112627</pub-id><pub-id pub-id-type="pmcid">PMC10146055</pub-id></element-citation></ref><ref id="B52-vaccines-13-00965"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ravindran</surname><given-names>R.</given-names></name><name name-style="western"><surname>McReynolds</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hammock</surname><given-names>B.D.</given-names></name><name name-style="western"><surname>Ikram</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ali</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bashir</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zohra</surname><given-names>T.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>W.L.W.</given-names></name><name name-style="western"><surname>Hartigan-O&#8217;Connor</surname><given-names>D.J.</given-names></name><etal/></person-group><article-title>Immune response dynamics in COVID-19 patients to SARS-CoV-2 and other human coronaviruses</article-title><source>PLoS ONE</source><year>2021</year><volume>16</volume><elocation-id>e0254367</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0254367</pub-id><pub-id pub-id-type="pmid">34242356</pub-id><pub-id pub-id-type="pmcid">PMC8270414</pub-id></element-citation></ref><ref id="B53-vaccines-13-00965"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krammer</surname><given-names>F.</given-names></name></person-group><article-title>A correlate of protection for SARS-CoV-2 vaccines is urgently needed</article-title><source>Nat. Med.</source><year>2021</year><volume>27</volume><fpage>1147</fpage><lpage>1151</lpage><pub-id pub-id-type="doi">10.1038/s41591-021-01432-4</pub-id><pub-id pub-id-type="pmid">34239135</pub-id></element-citation></ref><ref id="B54-vaccines-13-00965"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tanriover</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Do&#287;anay</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Akova</surname><given-names>M.</given-names></name><name name-style="western"><surname>G&#252;ner</surname><given-names>H.R.</given-names></name><name name-style="western"><surname>Azap</surname><given-names>A.</given-names></name><name name-style="western"><surname>Akhan</surname><given-names>S.</given-names></name><name name-style="western"><surname>K&#246;se</surname><given-names>S.</given-names></name><name name-style="western"><surname>Erdin&#231;</surname><given-names>F.S.</given-names></name><name name-style="western"><surname>Akal&#305;n</surname><given-names>E.H.</given-names></name><name name-style="western"><surname>Aksu</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac)</article-title><source>Lancet</source><year>2021</year><volume>398</volume><fpage>213</fpage><lpage>222</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(21)01429-X</pub-id><pub-id pub-id-type="pmid">34246358</pub-id><pub-id pub-id-type="pmcid">PMC8266301</pub-id></element-citation></ref><ref id="B55-vaccines-13-00965"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jara</surname><given-names>A.</given-names></name><name name-style="western"><surname>Undurraga</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Gonz&#225;lez</surname><given-names>C.</given-names></name><name name-style="western"><surname>Paredes</surname><given-names>F.</given-names></name><name name-style="western"><surname>Fontecilla</surname><given-names>T.</given-names></name><name name-style="western"><surname>Jara</surname><given-names>G.</given-names></name><name name-style="western"><surname>Pizarro</surname><given-names>A.</given-names></name><name name-style="western"><surname>Acevedo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Leo</surname><given-names>K.</given-names></name><name name-style="western"><surname>Araos</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile</article-title><source>N. Engl. J. Med.</source><year>2021</year><volume>385</volume><fpage>875</fpage><lpage>884</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2107715</pub-id><pub-id pub-id-type="pmid">34233097</pub-id><pub-id pub-id-type="pmcid">PMC8279092</pub-id></element-citation></ref><ref id="B56-vaccines-13-00965"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ibrahim</surname><given-names>K.Y.</given-names></name><name name-style="western"><surname>Moreira</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Santos</surname><given-names>C.F.D.</given-names></name><name name-style="western"><surname>Strabelli</surname><given-names>T.M.V.</given-names></name><name name-style="western"><surname>Beliz&#225;rio</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Pinto</surname><given-names>M.I.M.</given-names></name><name name-style="western"><surname>Marinho</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pereira</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Mello</surname><given-names>L.S.</given-names></name><name name-style="western"><surname>Ando</surname><given-names>M.C.</given-names></name><etal/></person-group><article-title>Immunogenicity of COVID-19 adsorbed inactivated vaccine (CoronaVac) and additional doses of mRNA BNT162b2 vaccine in immunocompromised adults compared with immunocompetent persons</article-title><source>Rev. Inst. Med. Trop. S&#227;o Paulo</source><year>2024</year><volume>66</volume><fpage>e24</fpage><pub-id pub-id-type="doi">10.1590/S1678-9946202466024</pub-id><pub-id pub-id-type="pmid">38656040</pub-id><pub-id pub-id-type="pmcid">PMC11027488</pub-id></element-citation></ref><ref id="B57-vaccines-13-00965"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Beitsch</surname><given-names>L.M.</given-names></name></person-group><article-title>Confidence and Receptivity for COVID-19 Vaccines: A Rapid Systematic Review</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><elocation-id>16</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines9010016</pub-id><pub-id pub-id-type="pmcid">PMC7823859</pub-id><pub-id pub-id-type="pmid">33396832</pub-id></element-citation></ref><ref id="B58-vaccines-13-00965"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wallace</surname><given-names>H.</given-names></name><name name-style="western"><surname>Mount</surname><given-names>P.F.</given-names></name></person-group><article-title>COVID-19 beliefs and vaccination uptake in dialysis patients: Lessons from an anonymous patient survey</article-title><source>Intern. Med. J.</source><year>2022</year><volume>52</volume><fpage>1488</fpage><lpage>1494</lpage><pub-id pub-id-type="doi">10.1111/imj.15636</pub-id><pub-id pub-id-type="pmid">34841628</pub-id></element-citation></ref><ref id="B59-vaccines-13-00965"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fisher</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Bloomstone</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Walder</surname><given-names>J.</given-names></name><name name-style="western"><surname>Crawford</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fouayzi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Mazor</surname><given-names>K.M.</given-names></name></person-group><article-title>Attitudes Toward a Potential SARS-CoV-2 Vaccine: A Survey of U.S. Adults</article-title><source>Ann. Intern. Med.</source><year>2020</year><volume>173</volume><fpage>964</fpage><lpage>973</lpage><pub-id pub-id-type="doi">10.7326/M20-3569</pub-id><pub-id pub-id-type="pmid">32886525</pub-id><pub-id pub-id-type="pmcid">PMC7505019</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="vaccines-13-00965-f001" orientation="portrait"><label>Figure 1</label><caption><p>Data flow diagram illustrating study design and cohorts. Reproduced from [<xref rid="B23-vaccines-13-00965" ref-type="bibr">23</xref>]. A total of 271 capillary blood samples were collected from 70 participants across five time points post-vaccination. Subjects were grouped into control (<italic toggle="yes">n</italic> = 33), hemodialysis (<italic toggle="yes">n</italic> = 13), and transplant (<italic toggle="yes">n</italic> = 24) cohorts, stratified by prior COVID-19 infection. Samples were collected at day 0 (pre-first dose), day 21/28 (pre-second dose), days 42 and 70 (2 and 4 weeks post-second dose), before any booster if applicable, and 6 months after the last dose.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="vaccines-13-00965-g001.jpg"/></fig><fig position="float" id="vaccines-13-00965-f002" orientation="portrait"><label>Figure 2</label><caption><p>Factors Associated with anti-spike and anti-nucleocapsid IgG responses. The heatmap visualization shows the results of Multivariate Linear Modeling (MLMM) analysis of IgG responses to spike (<bold>left panel</bold>) and nucleocapsid (<bold>right panel</bold>) antigens from SARS-CoV-2 (SARS2) and four common human coronaviruses (HCoVs): OC43, HKU1, 229E, and NL63. Each row represents a co-factor, (e.g., vaccine history, prior SARS-CoV-2 infection, clinical cohort, immunocompromised status), while each column corresponds to one of the combination of viral strain and surface antigens (S, N). Color intensity, scaled from 0 (light) to 1 (dark red), reflects the relative strength of association for each factor with the corresponding antibody response. MLMM was used to identify key predictors of antibody responses and to adjust for potential confounding factors.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="vaccines-13-00965-g002.jpg"/></fig><fig position="float" id="vaccines-13-00965-f003" orientation="portrait"><label>Figure 3</label><caption><p>Anti-spike and anti-nucleocapsid IgG antibodies for SARS-CoV-2 and common human coronaviruses. Concentrations of total anti-S (panel (<bold>A</bold>)) and anti-N (panel (<bold>B</bold>)) IgG for SARS-CoV-2 (dark green lines), OC43 (olive green lines), HKU1 (orange lines), 229E (brown lines), NL63 (golden lines) measured in control (<italic toggle="yes">n</italic> = 33), hemodialysis (<italic toggle="yes">n</italic> = 13), and transplant recipient (<italic toggle="yes">n</italic> = 24) cohorts. Day 0 corresponds to the first vaccination. Arrows show the mean days for the second (36.6 &#177; 34.1 days) and booster (154.3 &#177; 41.1 days) doses. Individual data points were pooled and fitted with spline curves for each cohort, and gray bands indicate 95% confidence intervals.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="vaccines-13-00965-g003.jpg"/></fig><fig position="float" id="vaccines-13-00965-f004" orientation="portrait"><label>Figure 4</label><caption><p>Anti-spike protein IgG distribution against SARS-CoV-2 and HCoVs IgG by cohort and COVID-19 status before vaccination. Individual distribution of total concentration of anti-S IgG for SARS-CoV-2 (dark green lines), OC43 (olive green lines), HKU1 (orange lines), 229E (brown lines), NL63 (golden lines) measured in the three studied groups after the first vaccine dose. Panel (<bold>A</bold>) shows subjects with no history of COVID-19 infection (<italic toggle="yes">n</italic> = 39) while Panel (<bold>B</bold>) displays those who reported a prior natural infection (<italic toggle="yes">n</italic> = 31). Day 0 corresponds to the first vaccination. Arrows show the mean days for the second (36.6 &#177; 34.1 days) and booster (154.3 &#177; 41.1 days) doses. Individual data points were pooled and fitted with spline curves for each cohort, and gray bands indicate 95% confidence intervals.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="vaccines-13-00965-g004.jpg"/></fig><fig position="float" id="vaccines-13-00965-f005" orientation="portrait"><label>Figure 5</label><caption><p>Anti-nucleocapsid protein IgG distribution against SARS-CoV-2 and HCoVs IgG by cohort and COVID-19 status before vaccination. Individual distribution of total concentration of anti-N IgG for SARS-CoV-2 (dark green lines), OC43 (olive green lines), HKU1 (orange lines), 229E (brown lines), NL63 (golden lines) measured in the three studied groups after first vaccine dose. Panel (<bold>A</bold>) shows subjects with no history of COVID-19 infection (<italic toggle="yes">n</italic> = 39) while Panel (<bold>B</bold>) displays those who reported a prior natural infection (<italic toggle="yes">n</italic> = 31). Day 0 corresponds to the first vaccination. Arrows show the mean days for the second (36.6 &#177; 34.1 days) and booster (154.3 &#177; 41.1 days) doses. Individual data points were pooled and fitted with spline curves for each cohort, and gray bands indicate 95% confidence intervals.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="vaccines-13-00965-g005.jpg"/></fig><fig position="float" id="vaccines-13-00965-f006" orientation="portrait"><label>Figure 6</label><caption><p>Anti-spike protein IgG distribution against SARS-CoV-2 and HCoVs IgG by cohort and vaccine type. Concentrations of total anti-S IgG for SARS-CoV-2 (dark green lines), OC43 (olive green lines), HKU1 (orange lines), 229E (brown lines), NL63 (golden lines) were measured in control (<italic toggle="yes">n</italic> = 33), hemodialysis (<italic toggle="yes">n</italic> = 13), and transplant (<italic toggle="yes">n</italic> = 24) cohorts by multiplex assay. Day 0 corresponds to the first vaccination. Arrows show the mean days for the second (36.6 &#177; 34.1 days) and booster (154.3 &#177; 41.1 days) doses. Among the subjects, 43 individuals (63.24%) were vaccinated with BNT162b2 (panel (<bold>A</bold>)), while 25 individuals (36.76%) received CoronaVac (panel (<bold>B</bold>)). Additionally, 8 subjects received homologous boosters, and seven received heterologous boosters. Individual data points were pooled and fitted with spline curves for each cohort, and gray bands indicate 95% confidence intervals.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="vaccines-13-00965-g006.jpg"/></fig><fig position="float" id="vaccines-13-00965-f007" orientation="portrait"><label>Figure 7</label><caption><p>Anti-nucleocapsid protein IgG distribution against SARS-CoV-2 and HCoVs IgG by cohort and vaccine type. Concentrations of total anti-S IgG for SARS-CoV-2 (dark green lines), OC43 (olive green lines), HKU1 (orange lines), 229E (brown lines), NL63 (golden lines) were measured in control (<italic toggle="yes">n</italic> = 33), hemodialysis (<italic toggle="yes">n</italic> = 13), and transplant (<italic toggle="yes">n</italic> = 24) cohorts by multiplex assay. Day 0 corresponds to the first vaccination. Arrows show the mean days for the second (36.6 &#177; 34.1 days) and booster (154.3 &#177; 41.1 days) doses. Among the subjects, 43 individuals (63.24%) were vaccinated with BNT162b2 (panel (<bold>A</bold>)), while 25 individuals (36.76%) received CoronaVac (panel (<bold>B</bold>)). Additionally, eight subjects received homologous boosters, and seven received heterologous boosters. Individual data points were pooled and fitted with spline curves for each cohort, and gray bands indicate 95% confidence intervals.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="vaccines-13-00965-g007.jpg"/></fig><table-wrap position="float" id="vaccines-13-00965-t001" orientation="portrait"><object-id pub-id-type="pii">vaccines-13-00965-t001_Table 1</object-id><label>Table 1</label><caption><p>Study Cohort: Demographics, Vaccination, and COVID-19 History. Adapted from [<xref rid="B23-vaccines-13-00965" ref-type="bibr">23</xref>]. We analyzed samples from 70 participants across three cohorts: control (<italic toggle="yes">n</italic> = 33), hemodialysis (HD; <italic toggle="yes">n</italic> = 13), and transplant (TR; <italic toggle="yes">n</italic> = 24). We stratified participants by prior COVID-19 history into positive (<italic toggle="yes">n</italic> = 31) and negative (<italic toggle="yes">n</italic> = 39) groups. In total, 271 capillary blood samples were available for analysis. Among vaccinated individuals, 43 received BNT162b2 (8 with homologous and 7 with heterologous boosters), and 25 received CoronaVac. We evaluated categorical variables using Pearson&#8217;s chi-squared and Fisher&#8217;s exact tests, and we present results as counts with percentages.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-bottom:solid thin;border-top:solid thin" rowspan="1" colspan="1">Characteristic</th><th align="right" valign="middle" style="border-bottom:solid thin;border-top:solid thin" rowspan="1" colspan="1">Control, <italic toggle="yes">n</italic> = 33&#160;<sup>1</sup></th><th align="right" valign="middle" style="border-bottom:solid thin;border-top:solid thin" rowspan="1" colspan="1">Hemodialysis, <italic toggle="yes">n</italic> = 13&#160;<sup>1</sup></th><th align="right" valign="middle" style="border-bottom:solid thin;border-top:solid thin" rowspan="1" colspan="1">Transplant, <italic toggle="yes">n</italic> = 24&#160;<sup>1</sup></th><th align="right" valign="middle" style="border-bottom:solid thin;border-top:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic>-Value&#160;<sup>2</sup></th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Age</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.150</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#160;&#160;&#160;&#160;18&#8211;24</td><td align="right" valign="middle" rowspan="1" colspan="1">6 (18%)</td><td align="right" valign="middle" rowspan="1" colspan="1">1 (7.7%)</td><td align="right" valign="middle" rowspan="1" colspan="1">3 (13%)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#160;&#160;&#160;&#160;25&#8211;44</td><td align="right" valign="middle" rowspan="1" colspan="1">21 (64%)</td><td align="right" valign="middle" rowspan="1" colspan="1">5 (38%)</td><td align="right" valign="middle" rowspan="1" colspan="1">11 (46%)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#160;&#160;&#160;&#160;45&#8211;65</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6 (18%)</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7 (54%)</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10 (42%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Sex</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.200</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#160;&#160;&#160;&#160;Female</td><td align="right" valign="middle" rowspan="1" colspan="1">19 (58%)</td><td align="right" valign="middle" rowspan="1" colspan="1">4 (31%)</td><td align="right" valign="middle" rowspan="1" colspan="1">10 (42%)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#160;&#160;&#160;&#160;Male</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14 (42%)</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9 (69%)</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14 (58%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Race</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#160;&#160;&#160;&#160;Asian</td><td align="right" valign="middle" rowspan="1" colspan="1">1 (3.0%)</td><td align="right" valign="middle" rowspan="1" colspan="1">0 (0%)</td><td align="right" valign="middle" rowspan="1" colspan="1">0 (0%)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#160;&#160;&#160;&#160;Black</td><td align="right" valign="middle" rowspan="1" colspan="1">15 (45%)</td><td align="right" valign="middle" rowspan="1" colspan="1">10 (77%)</td><td align="right" valign="middle" rowspan="1" colspan="1">24 (100%)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#160;&#160;&#160;&#160;White</td><td align="right" valign="middle" rowspan="1" colspan="1">7 (21%)</td><td align="right" valign="middle" rowspan="1" colspan="1">0 (0%)</td><td align="right" valign="middle" rowspan="1" colspan="1">0 (0%)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#160;&#160;&#160;&#160;Not reported</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10 (30%)</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (23%)</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Ethnicity</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.009</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#160;&#160;&#160;&#160;Hispanic or Latino</td><td align="right" valign="middle" rowspan="1" colspan="1">19 (58%)</td><td align="right" valign="middle" rowspan="1" colspan="1">10 (77%)</td><td align="right" valign="middle" rowspan="1" colspan="1">19 (79%)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#160;&#160;&#160;&#160;Non-Hispanic or Non-Latino</td><td align="right" valign="middle" rowspan="1" colspan="1">4 (12%)</td><td align="right" valign="middle" rowspan="1" colspan="1">0 (0%)</td><td align="right" valign="middle" rowspan="1" colspan="1">5 (21%)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#160;&#160;&#160;&#160;Not reported</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10 (30%)</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (23%)</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Education level</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#160;&#160;&#160;&#160;Less than high school</td><td align="right" valign="middle" rowspan="1" colspan="1">1 (3.0%)</td><td align="right" valign="middle" rowspan="1" colspan="1">5 (38%)</td><td align="right" valign="middle" rowspan="1" colspan="1">1 (4.2%)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#160;&#160;&#160;&#160;High school graduate</td><td align="right" valign="middle" rowspan="1" colspan="1">4 (12%)</td><td align="right" valign="middle" rowspan="1" colspan="1">3 (23%)</td><td align="right" valign="middle" rowspan="1" colspan="1">7 (29%)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#160;&#160;&#160;&#160;Higher education</td><td align="right" valign="middle" rowspan="1" colspan="1">9 (27%)</td><td align="right" valign="middle" rowspan="1" colspan="1">0 (0%)</td><td align="right" valign="middle" rowspan="1" colspan="1">15 (63%)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#160;&#160;&#160;&#160;Graduate education</td><td align="right" valign="middle" rowspan="1" colspan="1">3 (9.1%)</td><td align="right" valign="middle" rowspan="1" colspan="1">0 (0%)</td><td align="right" valign="middle" rowspan="1" colspan="1">0 (0%)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#160;&#160;&#160;&#160;Not reported</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16 (48%)</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5 (38%)</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (4.2%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Underlying conditions</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#160;&#160;&#160;&#160;None</td><td align="right" valign="middle" rowspan="1" colspan="1">27 (82%)</td><td align="right" valign="middle" rowspan="1" colspan="1">0 (0%)</td><td align="right" valign="middle" rowspan="1" colspan="1">1 (4.2%)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#160;&#160;&#160;&#160;At least one</td><td align="right" valign="middle" rowspan="1" colspan="1">6 (18%)</td><td align="right" valign="middle" rowspan="1" colspan="1">2 (15%)</td><td align="right" valign="middle" rowspan="1" colspan="1">6 (25%)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#160;&#160;&#160;&#160;Two or more</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0%)</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11 (85%)</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17 (71%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>COVID-19 positive before first fingerstick</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.053</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#160;&#160;&#160;&#160;Yes</td><td align="right" valign="middle" rowspan="1" colspan="1">10 (30%)</td><td align="right" valign="middle" rowspan="1" colspan="1">6 (46%)</td><td align="right" valign="middle" rowspan="1" colspan="1">15 (63%)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#160;&#160;&#160;&#160;No</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">23 (70%)</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7 (54%)</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9 (38%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>COVID-19 positive during the study</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&gt;0.900</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#160;&#160;&#160;&#160;Yes</td><td align="right" valign="middle" rowspan="1" colspan="1">8 (24%)</td><td align="right" valign="middle" rowspan="1" colspan="1">2 (15%)</td><td align="right" valign="middle" rowspan="1" colspan="1">5 (21%)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#160;&#160;&#160;&#160;Not reported</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25 (76%)</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11 (85%)</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19 (79%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Vaccine doses</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#160;&#160;&#160;&#160;One dose</td><td align="right" valign="middle" rowspan="1" colspan="1">11 (33%)</td><td align="right" valign="middle" rowspan="1" colspan="1">5 (38%)</td><td align="right" valign="middle" rowspan="1" colspan="1">2 (8.3%)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#160;&#160;&#160;&#160;Two doses</td><td align="right" valign="middle" rowspan="1" colspan="1">20 (61%)</td><td align="right" valign="middle" rowspan="1" colspan="1">4 (31%)</td><td align="right" valign="middle" rowspan="1" colspan="1">11 (46%)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#160;&#160;&#160;&#160;Fully vaccinated and one booster</td><td align="right" valign="middle" rowspan="1" colspan="1">2 (6.1%)</td><td align="right" valign="middle" rowspan="1" colspan="1">2 (15%)</td><td align="right" valign="middle" rowspan="1" colspan="1">10 (42%)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#160;&#160;&#160;&#160;Two or more boosters</td><td align="right" valign="middle" rowspan="1" colspan="1">0 (0%)</td><td align="right" valign="middle" rowspan="1" colspan="1">0 (0%)</td><td align="right" valign="middle" rowspan="1" colspan="1">1 (4.2%)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#160;&#160;&#160;&#160;Not reported</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0%)</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (15%)</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Vaccine type (prime schedule)</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.066</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#160;&#160;&#160;&#160;BNT162b2</td><td align="right" valign="middle" rowspan="1" colspan="1">25 (76%)</td><td align="right" valign="middle" rowspan="1" colspan="1">7 (64%)</td><td align="right" valign="middle" rowspan="1" colspan="1">11 (46%)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#160;&#160;&#160;&#160;CoronaVac</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8 (24%)</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 (36%)</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13 (54%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Booster schedule</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.700</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#160;&#160;&#160;&#160;Heterologous</td><td align="right" valign="middle" rowspan="1" colspan="1">0 (0%)</td><td align="right" valign="middle" rowspan="1" colspan="1">1 (50%)</td><td align="right" valign="middle" rowspan="1" colspan="1">6 (55%)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#160;&#160;&#160;&#160;Homologous</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (100%)</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (50%)</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5 (45%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr></tbody></table><table-wrap-foot><fn><p><sup>1</sup> n (%); <sup>2</sup> Fisher&#8217;s exact test; Pearson&#8217;s Chi-squared test.</p></fn></table-wrap-foot></table-wrap></floats-group></article></pmc-articleset>